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1. Introduction
This report describes and summarises results 
from the twenty-first proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of Salmonella and 
Campylobacter and is the tenth External Quality 
Assurance System (EQAS) conducted for these 
microorganisms (the first was EQAS 2006). In 
addition, the proficiency test includes 
categorization of the relevant Salmonella 
strains as presumptive AmpC-, ESBL-, or 
carbapenemase producing organisms, and 
identification of the Campylobacter species as 
either C. jejuni or C. coli. 
In addition, for the eighth time, an optional 
element was included, consisting of genotypic 
characterization of antimicrobial resistance 
genes by PCR and/or sequencing. This optional 
component included characterization of genes 
related to production of AmpC, ESBL- and 
carbapenemases in the Salmonella test strains. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or collaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by
performing Minimum Inhibitory Concentration
(MIC) determinations for all test strains in two
different occasions at the Technical University
of Denmark, National Food Institute (DTU
Food). These results were then verified by the
United States Food and Drug Administration
(FDA), Centre for Veterinary Medicine. Finally, a
fourth MIC determination was performed at
DTU Food after preparation of the agar stab
culture for shipment to participants to confirm
that the vials contained the correct strains with 
the expected MIC values. 
2) Evaluation is based on interpretations of
AST values determined by the participants. This
is in agreement with the method used by
Member States (MS) to report AST data to the
European Food Safety Authority (EFSA), and
complies with the main objective of this EQAS,
i.e. to evaluate and improve the comparability of
surveillance data on antimicrobial susceptibility
of Salmonella and Campylobacter reported to
EFSA by different laboratories, as stated in the
protocol.
3) The EURL-AR network agreed on setting the
accepted deviation level for laboratory
performance on AST to 5%. For the optional
genotypic characterisation, no specific
acceptance level has been set.
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant including also 
considerations related to any corrective actions 
introduced in the laboratory. Note, that since 
methods used for MIC determination have 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC 
of a specific antimicrobial when testing the 
same strains. If, however, the expected MIC is 
close to the breakpoint value for categorizing 
the strain as susceptible or resistant, a one-fold 
dilution difference - which is acceptable - may 
result in two different interpretations, i.e. the 
same strain can be categorized as susceptible 
and resistant. This result will be evaluated as 
correct in one case but incorrect when the 
evaluation is based on interpretation of MIC 
values. This report is based on evaluation of 
AST interpretations, therefore some participants 
may find their results classified as incorrect 
even though the actual MIC they reported is 
only a one-fold dilution away from the expected 
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MIC. In these cases, the participants should be 
confident about the good quality of their 
performance of AST by MIC. In the organization 
of the EQAS, we try to avoid these situations by 
choosing test strains with MIC values distant 
from the cut offs for resistance, which is not 
always feasible for all strains and all 
antimicrobials. Therefore, the EURL-AR 
network unanimously established in 2008 that if 
there are less than 75% correct results for a 
specific strain/antimicrobial combination, the 
reasons for this situation must be further 
examined and, on selected occasions explained 
in details case by case, these results may 
subsequently be omitted from the evaluation 
report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full 
list of laboratory codes is confidential and 
known only by relevant representatives of the 
EURL-AR and the EU Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2016 
A pre-notification (App. 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 1st July 
2016 by e-mail to the 43 laboratories in the 
EURL-AR-network including all EU countries 
and Iceland, Norway, Serbia, Switzerland and 
Turkey. All EU MS as well as Iceland, Norway, 
and Switzerland were represented as 
participants for both Salmonella and 
Campylobacter. In addition to the AST of 
Salmonella and Campylobacter, an optional 
genotypic characterization by PCR/sequencing 
of antimicrobial resistance genes of the AmpC-, 
ESBL- and carbapenemase-producing 
Salmonella test strains was offered.  
Appendix 2 shows that 29 of the 33 
participating NRLs were appointed by the 
individual Member States’ Competent Authority. 
Five additional laboratories were included; one 
from each of the following countries: Iceland, 
the Netherlands, Norway, Spain, and 
Switzerland. These were invited to take part in 
the EQAS 2016 on the basis of their 
participation in previous EQAS iterations and/or 
affiliation to the EU network. These laboratories 
were charged a fee for their participation in the 
EQAS, whereas the NRLs from EU Member 
States participated free of charge. 
Figure 1 illustrates that of the 31 participating 
countries, all tested both Salmonella and 
Campylobacter. Eleven laboratories 
participated in the optional genotypic 
characterisation of the ESC-producing 
Salmonella test strains (not illustrated in Figure 
1; see Appendix 2). 
The results from the NRLs designated by the 
MS are presented and evaluated in this report 
in addition to national reference laboratories in 
affiliated non-MS. In total, results from 31 
countries consisting of 31 laboratories 
submitting Salmonella results and 31 
laboratories submitting Campylobacter results. 
Results from the two laboratories not 
designated by the MS but enrolled in the EQAS 
are not further presented or evaluated in this 
report.
   6 
 
 
Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella 
and Campylobacter in 2016. 
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per bacterial 
species has been included in all EQAS 
iterations performed to date, representing an 
internal control. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and 
verified by the US Food and Drug 
Administration (FDA). When MIC-values were 
not in agreement but varied +/- one dilution-
step, the value obtained by DTU Food was 
selected as the reference value. The obtained 
MIC values served as reference for the test 
strains (App. 3a and 3b). Results from the 
following antimicrobials were not verified by 
FDA: cefepime, cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, 
ceftazidime/clavulanic acid, colistin, ertapenem, 
imipenem, temocillin, tigecycline and 
trimethoprim for Salmonella and furthermore, 
streptomycin for Campylobacter. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (App. 4b).  
The antimicrobials tested correspond to the 
panel of antimicrobials listed in Decision 
2013/652/EU.  
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document; M7-A10 
(2015) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Tenth 
Edition”; M100S, 26th ed. (2016) “Performance 
Standards for Antimicrobial Susceptibility 
Testing” (CLSI Supplement M100S) and 
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document VET01-A4 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Approved Standard – Fourth Edition). 
MIC results were interpreted by using the 
interpretative criteria listed in Decision 
2013/652/EU. Where values were not available, 
the list of interpretative criteria was 
supplemented with CLSI-interpretative criteria 
as or tentative values as described and 
indicated in the protocol (App. 4). No 
interpretative criteria were available to 
determine the interpretation of MIC-values from 
testing of cefepime. Results of ESC detection 
tests were interpreted according to the most 
recent EFSA recommendations, also included 
as an appendix in the EQAS protocol (Appendix 
4).  
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
azithromycin (AZI), cefepime (FEP), cefotaxime 
(FOT), cefotaxime/clavulanic acid (FOT/Cl), 
cefoxitin (FOX), ceftazidime (TAZ), 
ceftazidime/clavulanic acid (TAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET), 
tigecycline (TGC), temocillin (TRM) and 
trimethoprim (TMP). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system from 
Trek Diagnostic Systems Ltd, UK. For ESC 
confirmatory test, the analysis included MIC 
determination by microbroth dilution.  
For Campylobacter the following antimicrobials 
were included: ciprofloxacin (CIP), erythromycin 
(ERY), gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). 
MIC determination for the Campylobacter 
testing, was performed using the Sensititre 
systems from Trek Diagnostic Systems Ltd, UK, 
according to guidelines from the CLSI 
document M45-A2 (2010) “Methods for 
Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second 
Edition) and VET01-S2 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Second Informational Supplement). 
Participants of the Campylobacter EQAS were 
additionally requested to identify the species of 
the Campylobacter spp. as either C. jejuni or C. 
coli. 
2.4 Distribution 
On the 18th October 2016, bacterial strains in 
agar stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (App. 4a) were dispatched in double pack 
containers (class UN 6.2) to the participating 
laboratories. The shipment (UN3373, biological 
substances category B) was sent according to 
International Air Transport Association (IATA) 
regulations.  
2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately, store the agar 
stabs at 4ºC (dark) and the freeze-dried strains 
cool and dark until performance of AST. 
Information related to the handling of the test 
strains and reference strains (App. 4b, c, d, e) 
was made available. Participants receiving an 
ATCC reference strain were requested to save 
and maintain this strain for future proficiency 
tests. 
The participants were instructed to apply the 
interpretative criteria listed in the protocol (App. 
4). Instructions for interpretation of AST results 
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allowed for categorization of results as resistant 
or susceptible. Categorisations as ‘intermediate’ 
were not accepted.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
to wild-type and non-wild-type strains. 
As regards the method for performing the 
antimicrobial susceptibility testing, the protocol 
referred to Decision 2013/652/EU and 
instructed participants to perform a dilution 
method, i.e. microbroth dilution or agar dilution.  
A mandatory part of the proficiency test was to 
detect ESC-producing strains and interpret 
results according to the most recent EFSA 
recommendations as described in the protocol.  
Results from QC reference strains would 
consist of MIC values for the reference strains 
E. coli (ATCC 25922) and C. jejuni (ATCC
33560). The results were evaluated towards the
quality control ranges according to the relevant
guidelines; i.e. the CLSI documents VET01-S2
(2013) or M100S, 26th ed. (2016) (App. 5).
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
participating laboratories were requested to 
report the genes conferring resistance to 
extended-spectrum beta lactam antimicrobials. 
The organizers, however, decided to include 
none-ESC TEM-genes resulting in blaTEM-1 
registered as an expected gene, also. The 
genes listed in the table in the protocol (App. 
4b) were included in the test. Identification of 
additional genes not listed in the protocol was 
not evaluated by the database. The results 
were evaluated based on the actual genes and 
variants identified. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 2.1 
platform available at
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. The record sheet contained space 
for reporting the results obtained for the QC 
reference strains.  
In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and 
evaluations were made available to participants 
on the 20th December 2016. After this date, the 
participants were invited to login to retrieve an 
individual, database-generated report which 
contained an evaluation of the submitted results 
including possible deviations from the expected 
interpretations. Deviations in the interpretation 
as resistant or susceptible were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), ampC- or 
carbapenemase-producer. 
9 
3. Results
The participants were asked to report results, 
i.e. MIC values and the categorisation as
resistant or susceptible. Only the categorisation
was evaluated, whereas the MIC values were
used as supplementary information.
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the 
general analysis if there are less than 75% 
correct results based on strain/antimicrobial 
combination (see Appendix 7a and 7b for an 
overview of correct/incorrect results). In the 
present EQAS this occurred in three cases 
which have been examined and consequently 
omitted from the analysis; 1) S11.5/cefoxitin 
(expected interpretation was ‘susceptible’, 
however, 29% (9 laboratories) found the strain 
resistant to cefoxitin. All but two of the deviating 
interpretations were based on MIC values two 
steps from the expected; 2) S11.7/ceftazidime 
(expected interpretation was ‘resistant’, 
however, 45% (based on both panel 1 and 
panel 2) found the strain susceptible to 
ceftazidime. All of the deviating interpretations 
were based on MIC values one step from the 
expected; 3) C11.4/streptomycin (expected 
interpretation was ‘susceptible’, however, 90% 
of participants found the strain ‘resistant’ to 
streptomycin. The reported MIC-values varied 
from 4 and up to >16 (ECOFF is 4). Follow-up 
has been initiated to investigate the reason for 
this difference in obtained MIC-values. 
3.2 Methods  
The agar dilution method and MIC 
determination were evaluated together as they 
are both quantitative methods giving results 
corresponding to the MIC of the bacterial strain 
tested.  
In the Salmonella as well as the Campylobacter 
trial, 30 laboratories performed microbroth 
dilution and one performed agar dilution. 
With the aim to conclude on the strain’s 
presumptive ESBL, AmpC or carbapenemase 
phenotype, two panels of antimicrobials were 
included in the testing of the Salmonella strains. 
The test strains found resistant to cefotaxime, 
ceftazidime or meropenem on the first panel 
were additionally tested on the second panel 
according to the protocol indications.  
3.3 Deviations, overall 
The list of deviations is presented in Appendix 
8a and 8b. Figure 2 shows the total percentage 
of deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strains mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 2), only, for 2016 the Campylobacter 
internal control strain appears to have a high 
deviation level. The deviation levels in 2016 are 
acceptable for both the Salmonella and the 
Campylobacter trials.  
3.3.1 Salmonella trial  
For the Salmonella strains, 98.9% of the AST’s 
were interpreted correctly. The number of AST’s 
performed and the percentage of correct results 
for the individual strains in the EQAS, are listed 
in Table 1. Variations of obtained correct results 
ranged from 97.5-99.8% between the 
Salmonella strains. Table 2 illustrates the 
percentage of correct AST per antimicrobial by 
bacterial species. The level of correct AST was 
at 95.2% (tigecycline) or above, for all the 
Salmonella test strains.  
ESC-producing Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of 
deviations for antimicrobial susceptibility testing performed by participating laboratories.  
test for ESC-production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone 
and in combination with a -lactamase inhibitor. 
The MIC value for either antimicrobial agent 
(FOT or TAZ) tested in combination with 
clavulanic acid should be compared to the 
corresponding MIC when tested alone. Synergy 
is indicated if a three dilution steps difference is 
observed between the two MIC values (i.e. if 
the FOT:CTX/Cl or TAZ:TAZ/Cl ratio 8) (CLSI 
M100S Table 2A; Enterobacteriaceae). 
Participants were instructed to test strains 
presenting resistance to cefotaxime (FOT), 
ceftazidime (TAZ or meropenem (MERO) on 
the second panel of antimicrobials. 
The classification of the phenotypic results was 
based on the most recent EFSA 
recommendations indicating as indicated in the 
protocol (Appendix 4). 
In this EQAS, all laboratories uploaded results 
for the strains exhibiting resistance to the 
cephalosporins tested. 
The strains S-11.1 was a carbapenemase 
producer and the strains S-11.2, S-11.3, S-11.5, 
S-11.7 and S-11.8 were ESBL-producers.  
In total, the categorization as ESBL-, AmpC- or 
carbapenemase-producer was correct in almost 
all cases; i.e. out of 248 reported results, one 
was incorrect. Laboratory #19 indicated in the 
comments that by accident panel 2 was not 
performed, i.e. no phenotypic results supported 
the deviating categorization of the ESBL-
producer S-11.2 as an ‘ESBL + AmpC’. 
3.3.2 Campylobacter trial 
For the Campylobacter strains, 99.6% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
from 97.3-100% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial 
were all above 99.2%. 
The participants were requested to identify the 
Campylobacter species. All 31 laboratories 
delivered in total 248 results of which all were in 
accordance with the expected. 
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella (panel 1 
and panel 2) and Campylobacter. 
EQAS 2016 – Salmonella  EQAS 2016 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-11.1 639 97.5  C-11.1 (C. jejuni) 186 100.0 
S-11.2 634 99.8  C-11.2 (C. coli) 186 100.0 
S-11.3 640 98.9  C-11.3 (C. jejuni) 186 100.0 
S-11.4 428 98.8  C-11.4 (C. coli) 155 100.0 
S-11.5 609 98.5  C-11.5 (C. jejuni) 186 97.3 
S-11.6 428 99.8  C-11.6 (C. coli) 186 99.5 
S-11.7 577 99.7  C-11.7 (C. coli) 186 100.0 
S-11.8 641 99.2  C-11.8 (C. jejuni) 186 100.0 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 100.0 - 
Azithromycin 100.0 -  
Cefotaxime 100.0 - 
Cefoxitin 96.8 -  
Ceftazidime 96.2 - 
Chloramphenicol 99.6 - 
Ciprofloxacin 100.0 99.2 
Colistin 99.6 -  
Ertapenem 98.9 -  
Erythromycin - 100.0 
Gentamicin 99.6 99.6 
Imipenem 96.7 -  
Meropenem 100.0 -  
Nalidixic acid 100.0 99.6 
Streptomycin - 99.5 
Sulphonamides 98.8 -  
Temocillin 100.0 -  
Tetracycline 100.0 99.6 
Tigecycline 95.2 - 
Trimethoprim 99.6 - 
 
3.4 Deviations by laboratory 
Figure 3 and 4 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
deviating results in the antimicrobial 
susceptibility tests. 
3.4.1 Salmonella trial  
All 31 participating laboratories obtained a 
result below the acceptance limit at 5% 
deviations for the Salmonella strains. The 
maximum percentage of deviations was at 
4.6%, presenting a very good result across the 
EURL-AR network. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 30 of 31 participating 
laboratories performed acceptably, with 28 
laboratories having no deviations (Figure 4). 
One laboratory presented a deviation level 
above the 5% acceptance level (#36). This 
laboratory was, however not regarded as an 
outlier. 
3.5 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 5).  
Obtained values from the participants’ testing of 
the QC strains are listed in Appendix 6a and 6b, 
and in Table 4 and 5. For the Salmonella and 
Campylobacter trial, 31 and 29 laboratories, 
respectively, uploaded data from QC-testing on 
the relevant reference strain. 
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Table 3: Overview of ESBL-, AmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, AmpC- and carbapenemase-producing Salmonella strains.  
Fields shaded in grey with numbers in italics indicate an unexpected result. 
Strain code S-11.1 S-11.2 S-11.3 S-11.5 S-11.7 S-11.8 
ESC-genes harboured in the 
test strain 
blaTEM-1 
blaOXA-48 
blaSHV-2 
blaTEM-1B 
blaCTX-M-9 
blaCTX-M-65 blaCTX-M-8 
blaCTX-M-15 
blaOXA-1/OXA-30 
ESBL-, AmpC- and carbapenemase-
producing strain – expected results 
carba-
penemase ESBL ESBL ESBL ESBL ESBL 
O
bt
ai
ne
d 
re
su
lts
 
Confirmed ESBL-producer - 30/31 (97%) 31/31 (100%) 31/31 (100%) 31/31 (100%) 31/31 (100%) 
Confirmed ESBL + AmpC-
producer - 1/31 (3%) - - - - 
Confirmed AmpC-producer - - - - - - 
Confirmed carbapenemase-
producer 31/31 (100%) - - - - - 
Confirmed unusual 
phenotype - - - - - - 
Not ESBL-, AmpC-  
or carbapenemase-producing - - - - - - 
 
 
Figure 3: Individual participants’ deviations in percent of their total number of Salmonella AST’s.  
 
Figure 4: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 4 Obtained values for AST of E. coli ATCC 25922. 
AMP; ampicillin, FEP; cefepime FOT; cefotaxime, FOX; 
cefoxitin, TAZ; ceftazidime, CHL; chloramphenicol, CIP; 
ciprofloxacin, COL; colistin, ERT: ertapenem, GEN; 
gentamicin, IMI; imipenem, MER; meropenem, NAL; 
nalidixic acid, SMX; sulphonamides, TET; tetracycline, 
TGC; tigecycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above 
upper QC 
limit 
Panel 1, AMP 1/31 (3%) - 1 step
Panel 1, FOT 1/31 (3%) - 1 step
Panel 1, TAZ 0/31 (0%) - -
Panel 1, CHL 0/31 (0%) - - 
Panel 1, CIP 0/31 (0%) - - 
Panel 1, COL 0/31 (0%) - - 
Panel 1, GEN 1/31 (3%) 1 step - 
Panel 1, MER 0/31 (0%) - - 
Panel 1, NAL 0/31 (0%) - - 
Panel 1, SMX 2/30 (7%) - 1 step
Panel 1, TET 0/31 (0%) - - 
Panel 1, TGC 1/31 (3%) - 1 step
Panel 1, TMP 3/31 (10%) 1 step - 
Panel 2, FEP 0/29 (0%) - - 
Panel 2, FOT 1/28 (4%) - 1 step
Panel 2, FOX 0/29 (0%) - - 
Panel 2, TAZ 0/29 (0%) - - 
Panel 2, ERT 0/29 (0%) - - 
Panel 2, IMI 0/29 (0%) - - 
Panel 2, MER 0/29 (0%) - - 
Table 5 Obtained values for AST of C. jejuni ATCC 33560. 
CIP; ciprofloxacin, ERY; erythromycin, GEN; gentamicin, 
NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above upper 
QC limit 
CIP 1/29 (3%) - 1 step
ERY 0/29 (0%) - - 
GEN 2/25 (8%) 2 steps - 
NAL 1/28 (4%) 1 step - 
TET 2/28 (7%) - 1 step
Appendix 6a presents the results for the 
reference strain E. coli ATCC 25922. Eight 
laboratories produced in all ten values outside 
the QC-limit. Table 4 illustrates the obtained 
results which are fully presented in Appendix 
6a.  
Table 5 presents the proportion of the 
laboratories submitting AST-results for the C. 
jejuni reference strain ATCC 33560 with results 
below or above the QC interval. Six deviations 
were seen from five different laboratories. 
3.6 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 11 
laboratories participated. In Appendix 9, 
information is collected on detected genes, 
genes which were tested but not detected, 
primers used, and references for the method 
used. Three laboratories performed whole 
genome sequencing of the ESC-producing 
Salmonella whereas the remaining eight 
laboratories indicated the use of various types 
of conventional PCR to identify the relevant 
genes. 
Table 6 indicate the obtained results, both on 
gene and variant level. Moreover, Figure 5 
indicates that ten discordant results related to 
Figure 5: Individual participants’ deviations in percent of 
their total number of results from the detected genes. In 
addition, laboratory #4 tested but did not detect blaOXA-48  for 
strain S-11.1. 
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14 
the gene variants were submitted by seven 
different laboratories. These were related to 
variants of the blaSHV and the blaCTX-M-genes. 
Table 6: Results from the participation of nine laboratories in the optional genotypic characterisation component of the 
EQAS 
Strain code Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Unexpected 
genes/variants identified 
S-11.1
blaTEM-1/1B 8/8 (100%) 7/7 (100%) blaOXA-48 tested but not detected blaOXA-48 10/11 (91%) 10/11 (91%) 
S-11.2 blaSHV-2/2a 11/11 (100%) 7/10 (70%) blaSHV-12 
S-11.3
blaTEM-1/1B 9/9 (100%) 8/8 (100%) 
blaCTX-M-9 11/11 (100%) 11/11 (100%) 
S-11.5 blaCTX-M-65 11/11 (100%) 6/10 (60%) 
blaCTX-M-9 
blaCTX-M-14 
S-11.7 blaCTX-M-8 10/10 (100%) 10/10 (100%) 
S-11.8
blaCTX-M-3 10/10 (100%) 7/10 (70%) blaCTX-M-1 
blaCTX-M-15 blaOXA-1 or blaOXA-30 6/6 (100%) 6/6 (100%) 
4. Discussion
In 2016, the number of EQAS participants was 
the same as in 2015, allowing the comparison 
between the two EQAS periods.  
As also specified in the EU regulation 
2013/652/EU, all participants in the present 
EQAS performed AST by dilution methods, 
primarily as microbroth determination.  
This 2016 proficiency test is the third possibility 
of testing Salmonella and Campylobacter 
strains with the panels designed to follow the 
requirements of Decision 2013/652/EU. This 
allows for the possibility that the experience 
obtained since the introduction of the legislation 
and the focus it has created on AST in the 
laboratories has had an impact on the generally 
satisfactory results obtained at the present 
EQAS. 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
98.9%. All (n=31) participants obtained 
satisfactory results according to the level of 
acceptance (<5% deviation). When comparing 
between the antimicrobials, the testing of 
tigecycline appeared to cause most problems 
(95.2% correct results).  
As indicated in Figure 2, the overall quality of 
the results in the 2016-EQAS would appear to 
be at the same high level as in 2015, also, the 
measure when comparing results obtained from 
testing the internal control strain indicates a 
steady and very good quality of results.  
As indicated by Figure 3, all laboratories 
exhibited very good results with deviation levels 
below 5%. Follow-up has therefore not been 
necessary based on these results, and none of 
the laboratories were defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations. Within the submitted 
results, trimethoprim appeared to have most 
results outside the QC-range, and for cefepime 
one result was two steps above the QC-range.  
Follow up on previous EQAS results is not 
relevant as no laboratories had deviation levels 
for the AST results above the acceptance limit 
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in EQAS 2015.  
ESC-producing Salmonella test strains 
The detection of ESC-producing 
microorganisms remains to be important and is 
a mandatory part of this EQAS.  
Of the six Salmonella test strains relevant for 
this component of the EQAS (S-11.1, S-11.2, S-
11.3, S-11.5, S-11.7, and S-11.8), five were 
ESBL-phenotypes and one was a 
carbapenemase phenotype. The testing and 
interpretation of results for these strains 
appeared not to cause difficulties for any of the 
participating laboratories.  
Of the 31 laboratories which tested Salmonella, 
one laboratory (#19) submitted one incorrect 
AmpC-, ESBL-, carbapenemase categorization 
(App. 8a). This deviation was not based on 
phenotypic test results as the laboratory 
indicated in the comments that by accident 
testing using panel 2 was not performed.  
Even if no acceptance limit has been defined 
for this component of the EQAS, the overall 
result that 99.6% of the obtained results were 
as expected, is satisfactory. 
4.2 Campylobacter trial  
For the Campylobacter component of this 
year’s EQAS, 31 laboratories submitted results 
leading to an overall percentage of correct AST 
results at 99.6%. The performance varied from 
no deviations up to 6.4% deviations, with 30 
laboratories performing satisfactorily according 
to the established acceptance range.  
It appears that there has been a decrease in 
the level of deviations for the overall AST result, 
however, deviations were observed in the 
results obtained from testing the internal control 
strain.  
One laboratory (#36) obtained deviation levels 
above 5%. For this laboratory, however, the 
values obtained for the QC-strain did not 
indicate methodical issues to be the reason for 
the obtained deviations. The EURL-AR has 
been in contact with this laboratory to identify 
the possible cause of this unsatisfactory 
performance and to improve the quality of 
results. The high deviation level was caused by 
three deviations on the same strain. This had 
been tested four times and for four of the 
antimicrobials, MIC-values indicating both 
susceptible and resistant were obtained. 
Investigations are ongoing to identify the issue 
that might have caused this. 
All participating laboratories except two (#23 
and #34) uploaded data from tests performed 
on the C. jejuni reference strain and the 
proportion of results within the QC intervals was 
95.7%. Five of the six values outside the QC 
intervals were one step below or above the QC-
limits, and one was two dilution steps above the 
QC-limits. The laboratories obtaining these 
values should follow-up on these high/low 
values, and it is suggested that these values 
are monitored over time to ensure that the tests 
render a reliable result for the particular 
antimicrobial. 
Laboratory #36 which was regarded as an 
outlier for the 2015 Campylobacter EQAS with 
deviation levels at 21.3% increased their 
performance in the 2016-iteration and due to 
three deviation on the same strain, they 
obtained a deviation level at 6.4%.  
4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, communication has been 
ongoing to improve laboratory detection and 
confirmation of ESBL- and AmpC-producing 
Enterobacteriaceae.  
Furthermore, the agenda now is focusing at the 
implementation of detection of carbapenemase 
resistant organisms and the importance of 
determining the identity of the genes 
responsible for the carbapenemase production 
by molecular methods.  
The optional genotypic characterisation offered 
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as a supplementary part of this EQAS should 
therefore be seen as an important possibility for 
the NRL-AR’s to introduce this method in the 
laboratory and thereby be at the forefront when 
the method proposals are adopted. This year, 
eleven laboratories participated in this optional 
EQAS component and even though no 
acceptance limit has been defined, the 94% 
correct results (N=167) appears to be a 
satisfactory result. As for the unexpected 
genes/variants identified (see Table 6), the 
indicated bla-genes belong to the same CTX-M-
group as the expected variant. 
5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
Again this year, this goal was reached for 
Salmonella and seems within reach for 
Campylobacter.  
Compared to the EQAS 2015, the performance 
of the NRL’s in 2016 appears to be at the same 
high level for Salmonella AST’s (98.9% in 2016 
and 99.3% in 2015) (Figure 2). Regarding 
Campylobacter AST’s, the performance of the 
NRL’s also appear to have improved from 2015 
to 2016, with a change in deviation level from 
1.6% (2015) to 0.4% (2016). For the 
Campylobacter AST, one laboratory (#36) will 
continue to follow-up and perform re-testing 
internally to troubleshoot and identify the issue 
that caused the deviations.  
The test covering the identification of the 
phenotype of Salmonella test strains producing 
beta-lactamases of the ESBL-, AmpC, and 
carbapenemase-type rendered good results 
(99.5% correct categorizations). This is a 
priority area within the EURL-AR activities, and 
it is encouraging to see acceptable results in 
identifying and categorizing these strains. 
Eleven NRLs participated in the EQAS 
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae presenting satisfactory 
results.  
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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G00-06-001/01.12.2014 
EURL-AR EQAS pre-notification 
EQAS 2016 FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC 
CHARACTERISATION  
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 
3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Laboratories designated to be 
NRL-AR do not need to sign up to participate but are automatically regarded as participants. Should 
there be changes in relation to your level of participation in previous years, please contact the 
EQAS-Coordinator. The EURL-AR will be able to cover the expenses for one parcel per EU 
Member State. Therefore, countries with more than one laboratory registered on the EURL-AR 
contact-list will be contacted directly to confirm which laboratory will be included for participation 
free of charge.  
The invitation to participate in the proficiency test is extended to additional participants from 
official NRLs and participants from laboratories which are involved in the network but are not 
designated NRLs (cost for participation will be 100 EURO). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and for new participants also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2016. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 9th 2016 via the password-protected website.  
Appendix 1, page 1 of 2
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Next EQAS: The next EURL-AR EQAS that we will send out to the EURL-AR network focuses at 
antimicrobial susceptibility testing of E. coli, enterococci and staphylococci and is expected to be 
sent to participating laboratories in June 2017. 
Please contact me if you have comments or questions regarding the EQAS 
Sincerely, 
Susanne Karlsmose Pedersen (suska@food.dtu.dk) 
EQAS-Coordinator 
Appendix 1, page 2 of 2
Appendix 2, page 1 of 1
Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X X Austrian Agency for Health and Food Safety Austria
X X X Institute of Public Health Belgium
X X - National Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X* - X DTU National Food Institute Denmark
X X - Danish Veterinary and Food Administration, DVFA Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X X - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X - Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X X Laboratoire national de Santé Luxembourg
X X - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X* X* - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Hygiene and Veterinary Public Health Romania
X* X* - Institute for Diagnosis and Animal Health Romania
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X* - - Centro Nacional de Alimentación (AECOSAN) Spain
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X* X* - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X* X* - Public Health England United Kingdom
X X - Animal Plant Health Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
* Submitted results were not included in the current report (allows for one dataset per country, only)
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Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Azithromycin Cefepime Cefotaxime Cefotaxime/clav F:F/C Cefoxitin Ceftazidime Ceftazidime/clav T:T/C Chloramphenicol Ciprofloxacin Colistin Ertapenem
AMP AZI FEP FOT F/C ratio FOX TAZ T/C ratio CHL CIP COL
EURL S-11.1 >64 RESIST 64 RESIST 4 4 RESIST 4/4 <8 8 SUSC 2 SUSC 1/4 <8 4 SUSC >8 RESIST  <= 1 SUSC 2 RESIST
EURL S-11.2 >64 RESIST 8 SUSC 2 8 RESIST 0.06/4 >=8 4 SUSC 8 RESIST 0.25/4 >=8 >128 RESIST 0.03 SUSC 2 SUSC 0.015 SUSC
EURL S-11.3 >64 RESIST 8 SUSC 2 8 RESIST 0.06/4 >=8 4 SUSC 1 SUSC 0.25/4 <8 8 SUSC 0.25 RESIST  <= 1 SUSC 0.015 SUSC
EURL S-11.4 >64 RESIST 8 SUSC <=0.25 SUSC 2 SUSC 1 SUSC 4 SUSC 0.06 SUSC 16 RESIST
EURL S-11.5 >64 RESIST 16 SUSC 4 >64 RESIST 0.25/4 >=8 8 SUSC 8 RESIST 0.5/4 >=8 >128 RESIST 0.5 RESIST  <= 1 SUSC 0.015 SUSC
EURL S-11.6  <= 1 SUSC 8 SUSC <=0.25 SUSC 2 SUSC  <0.5 SUSC 8 SUSC 0.03 SUSC  <= 1 SUSC
EURL S-11.7 >64 RESIST 8 SUSC >32 >64 RESIST 0.12/4 >=8 8 SUSC 4 RESIST 0.5/4 >=8 4 SUSC 0.03 SUSC  <= 1 SUSC 0.015 SUSC
EURL S-11.8 >64 RESIST 64 RESIST 32 >64 RESIST 0.25/4 >=8 4 SUSC 16 RESIST 0.25/4 >=8 >128 RESIST 1 RESIST  <= 1 SUSC 0.03 SUSC
Gentamicin IMIPENEM MEROPENEM Nalidixic acid Sulfamethoxazole TEMOCILLIN Tetracycline TIGECYCLINE Trimethoprim
GEN IMI MER NAL SMX TRM TETRA TGC TMP ESBL-category Relevant genes
EURL S-11.1 32 RESIST 4 RESIST 2 RESIST >128 RESIST >1024 RESIST >128 RESIST >64 RESIST 1 SUSC >32 RESIST
EURL S-11.2  <= 0.25 SUSC 0.25 SUSC  <= 0.03 SUSC 2 SUSC 32 SUSC 8 SUSC  <= 2 SUSC 0.5 SUSC  <= 0.25 SUSC
EURL S-11.3  <= 0.25 SUSC 0.12 SUSC  <= 0.03 SUSC >128 RESIST 32 SUSC 4 SUSC 64 RESIST 0.5 SUSC  <= 0.25 SUSC
EURL S-11.4  <= 0.25 SUSC 0.06 SUSC 8 SUSC >1024 RESIST >64 RESIST 2 RESIST >32 RESIST
EURL S-11.5 8 RESIST 0.12 SUSC  <= 0.03 SUSC >128 RESIST >1024 RESIST 16 SUSC >64 RESIST 2 RESIST >32 RESIST
EURL S-11.6  <= 0.25 SUSC  <= 0.03 SUSC 4 SUSC 32 SUSC  <= 2 SUSC 0.5 SUSC  <= 0.25 SUSC
EURL S-11.7 0.5 SUSC 0.25 SUSC 0.06 SUSC 2 SUSC >1024 RESIST 8 SUSC >64 RESIST 1 SUSC 0.5 SUSC
EURL S-11.8 32 RESIST 0.25 SUSC 0.06 SUSC >128 RESIST >1024 RESIST 16 SUSC >64 RESIST 1 SUSC >32 RESIST
Resistant
CTX M-8
CTX M-3 + 
OXA-1
carbapenemase-producing
ESBL-producing
ESBL-producing
ESBL-producing
ESBL-producing
ESBL-producing CTX M-9TEM-1B
OXA-48
TEM-1 
SHV-2
CTX M-65
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Reference values (MIC-value and interpretation) - Campylobacter 
Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. jejuni EURL C-11.1  <= 0.12 SUSC  <= 1 SUSC 0.25 SUSC 4 SUSC 1 SUSC 1 SUSC
C. coli EURL C-11.2 16 RESIST >128 RESIST 0.5 SUSC 64 RESIST 2 SUSC >64 RESIST
C. jejuni EURL C-11.3 8 RESIST  <= 1 SUSC 0.5 SUSC >64 RESIST 2 SUSC 64 RESIST
C. coli EURL C-11.4 8 RESIST  <= 1 SUSC 1 SUSC >64 RESIST 2 SUSC 16 RESIST
C. jejuni EURL C-11.5 4 RESIST  <= 1 SUSC  <= 0.12 SUSC 64 RESIST 0.5 SUSC 32 RESIST
C. coli EURL C-11.6 0.25 SUSC  <= 1 SUSC 1 SUSC 8 SUSC >16 RESIST 1 SUSC
C. coli EURL C-11.7 >16 RESIST 2 SUSC 1 SUSC >64 RESIST 4 SUSC >64 RESIST
C. jejuni EURL C-11.8  <= 0.12 SUSC  <= 1 SUSC 0.25 SUSC 8 SUSC 1 SUSC 64 RESIST
Resistant
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EURL-AR External Quality Assurance System 2016 
- Salmonella, Campylobacter and optional genotypic characterisation 
 
Id: «Lab_no_» 
«Name» 
«Institute__»  
«Country» 
Kgs. Lyngby, October 2016 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2016. Upon arrival to your 
laboratory, the strains should be stored dark and at 4C for stabs, and dark and cool for lyophilized 
strains. Charcoal swabs must be subcultured straight away.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we send to 
you by performing antimicrobial susceptibility testing. The ESBL-producing Salmonella strains 
should be characterised genotypically (optional) according to the description in the protocol. In the 
protocol you can find detailed description of the procedures to follow. Additionally, you can find a 
description of the procedure to enter your results into the interactive web database. For accessing 
the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than December 9th 2016.  
 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact us for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose Pedersen 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance 
External Quality Assurance System (EQAS) 2016 
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PROTOCOL 
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 
1 INTRODUCTION  ................................................................................................................... 1 
2 OBJECTIVES  .......................................................................................................................... 2 
3 OUTLINE OF THE SALM/CAMP EQAS 2016  .................................................................. 2 
3.1    Shipping, receipt and storage of strains  ........................................................................ 2 
3.2 QC reference strains  ...................................................................................................... 2 
3.4 Antimicrobial susceptibility testing  .............................................................................. 3 
3.5 Optional genotypic characterisation  ............................................................................. 5 
4 REPORTING OF RESULTS AND EVALUATION  ........................................................... 5 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE  ............................. 6 
APPENDIX  ........................................................................................................................................ 8 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of Salmonella and Campylobacter is among the tasks of 
the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The 
Salmonella/Campylobacter EQAS 2016 will include AST of eight Salmonella and Campylobacter 
strains and AST of reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 
(CCM 6214).  
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
Appendix 4b, page 1 of 8
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the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to Salmonella and 
Campylobacter. Further objectives are to evaluate and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella and Campylobacter reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE SALM/CAMP EQAS 2016 
3.1    Shipping, receipt and storage of strains 
In October 2016, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight Salmonella and Campylobacter strains from the National Food 
Institute. This parcel will also contain reference strains, but only for participants who did not 
receive them previously. All strains belong to UN3373, Biological substance, category B. Extended 
spectrum beta-lactamase (ESBL)-producing strains as well as carbapenemase producing strains are 
included in the selected material and are part of the optional EQAS-item, consisting of 
characterization of genes conferring ESBL- or carbapenemase production.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.2 QC reference strains 
For a suggested procedure for reconstitution of the lyophilised, please refer to the document 
‘Instructions for opening and reviving lyophilised cultures’ on the EURL-AR-website (see 
www.eurl-ar.eu). 
Note that, for the testing of the E. coli ATCC25922 reference strain, the two compounds, 
sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from 
the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 
for sulfisoxazole. 
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3.4 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below. 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For interpretation of the results, use the cut-off 
values listed in Tables 1, 2 and 3 (except where indicated) represent the current epidemiological 
cut-off values developed by EUCAST (www.eucast.org), and allow categorisation of bacterial 
isolates into two categories; resistant or susceptible. A categorisation as intermediate is not 
accepted.  
As the current regulation and recommendations focus on MIC testing only, results obtained by disk 
diffusion cannot be submitted. 
3.4.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
Table 1: Antimicrobials recommended for AST of Salmonella spp. and interpretative criteria according to 
table 1 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Ampicillin (AMP) 8 
Azithromycin (AZI) 16* 
Cefotaxime (FOT) 0.5 
Ceftazidime (TAZ) 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Colistin (COL) 2 
Gentamicin (GEN) 2 
Meropenem (MERO) 0.125 
Nalidixic acid (NAL) 16 
Sulfonamides (SMX) 256** 
Tetracycline (TET) 8 
Tigecycline (TGC) 1*** 
Trimethoprim (TMP) 2 
* Tentative value 
** CLSI M100 Table 2A 
*** Data from EUCAST is available for S. Enteritidis, S. Typhimurium, S. Typhi and S. Paratyphi (for the 
purpose of this proficiency test, the ECOFF at 1 is applied) 
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Table 2: Antimicrobials recommended for additional AST of Salmonella spp. resistant to cefotaxime, 
ceftazidime or meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Cefepime, FEP Not available* 
Cefotaxime, FOT 0.5 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 2 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 1 
Meropenem, MERO 0.125 
Temocillin, TRM 32** 
* Participants are requested to upload the MIC value obtained without selecting an interpretation
** Tentative value
Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 for results obtained by MIC-determination should allow 
detection of plasmid-mediated quinolone resistant test strains.  
Beta-lactam- and carbapenem resistance  
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem and should be performed by testing the second panel 
of antimicrobials (Table 2 in this document corresponding to Table 4 in Commission Implementing 
Decision 2013/652/EU). 
Confirmatory test for AmpC-, ESBL- and carbapenemase production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as i) a ≥ 3 twofold concentration decrease in an MIC for 
either antimicrobial agent tested in combination with clavulanic acid vs. the MIC of the agent when 
tested alone (MIC FOT : FOT/Cl or TAZ : TAZ/Cl ratio ≥ 8) (CLSI M100 Table 3A, Tests for 
ESBLs). The presence of synergy indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO). 
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EURL-AR Workshop 2016, http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf and in the appendix to this protocol). 
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3.4.2 Campylobacter   
For AST of Campylobacter, MIC methods should be applied, i.e. broth or agar dilution methods 
using incubation at 36-37ºC for 48 hours or 42ºC for 24 hours.  
Table 3: Antimicrobials recommended for AST of Campylobacter jejuni and C. coli and 
interpretative criteria according to table 1 in EC regulation 652/2013 
Antimicrobial C. jejuni C. coli 
MIC (µg/mL) (R>) MIC (µg/mL) (R>) 
Ciprofloxacin (CIP) 0.5 0.5 
Erythromycin (ERY) 4 8 
Gentamicin (GEN) 2 2 
Nalidixic acid (NAL) 16 16 
Streptomycin (STR) 4 4 
Tetracycline (TET) 1 2 
 
 
Identification of Campylobacter species 
Species identification of the Campylobacter test strains must be performed by the NRLs using in-
house methods or adopting the protocol available on the EURL-AR website under: http://eurl-
ar.eu/233-protocols.htm. 
3.5 Optional genotypic characterisation 
For the optional genotypic characterisation of the AmpC-, ESBL- or carbepenemase producing 
Salmonella test strains, the requested results are the genes conferring AmpC-, ESBL- or 
carbepenemase -production harboured in the test strains. The genes included in the test are the 
following: ACC, ACT, CARB, CMY, CTX-M, DHA, FOX, GES, IMP, KPC, MOX, NDM, OXA, 
PER, SCO, SHV, TEM, VEB, and VIM. The database lists the relevant variants of the genes.   
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected gene (ACC-, ACT-, CARB-, etc.) as 
well as the variant identified.  
The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database.  
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 9th 2016. After 
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the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose Pedersen 
National Food Institute,  
Technical University of Denmark 
Søltofts Plads, Building 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS start web page (http://eurl-ar.food.dtu.dk), write your username and 
password (lower-case) and press enter. Your username and password are indicated in the letter 
following your strains. Do not hesitate to contact us if you experience problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
Click on either “Salmonella test results” or “Campylobacter test results” for input of test results.  
Click on "Start of Data Entry - Methods” 
In the next page, you navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
When submitting Campylobacter results, fill in the incubation conditions applied for susceptibility 
testing of Campylobacter – 36°C/48h or 42°C/24h. 
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Click on "save and go to next page” 
In the data entry pages, you enter the species (for Campylobacter only), the obtained MIC-value 
and the interpretation (R, resistant or S, susceptible) for each Salmonella and Campylobacter strain. 
For Salmonella, remember to also report the results for the ESBL detection tests. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through them and make corrections if necessary. Remember to 
save a page if you make corrections. If you press home a page without saving changes, you will see 
an error screen. In this case, click on “save“ to save your results, browse back to the page and then 
continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields as  YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database. 
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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APPENDIX 
Criteria for interpretation of Salmonella, panel 2 results 
Please refer to the full presentation at http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
 
Does your laboratory have an accreditation for performing Salmonella AST?   Yes     No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth microdilution    
  Agar dilution 
 
 Brand of microbroth plates/agar:        
 Incubation conditions:      °C/     h 
 
How many Salmonella isolates does your laboratory annually isolate:       
 
How many Salmonella isolates does your laboratory annually test for antimicrobial susceptibility by 
a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM          
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS: 
 Broth microdilution 
 Agardilution 
 
Brand of microbroth plates/agar:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 11.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                  
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 11.X 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
1st panel 
 
 
Ampicillin, AMP        
Azithromycin, AZI       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX*       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
* for the testing of the E. coli ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are 
regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated 
against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3). 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-11.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-11.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-11.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-11.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Nalidixic acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
Erythromycin        
Gentamicin       
Nalidixic acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                    
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1)
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue (see http://www.sci.muni.cz)
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S24, January 2014 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A9, January 2012 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC
validation)
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides
 Periodically perform colony counts to check the inoculum preparation procedure
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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Quality Control ranges for ATCC reference strains
Antimicrobial Microbroth      (36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution   
(36-37°C/48h)
Agar dilution   
(42°C/24h)
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
Campylobacter jejuni ATCC 33560
MIC ranges (µg/mL)  are according to CLSI (VET01-S2) 
Tigecycline, TGC 0.03-0.25
Trimethoprim, TMP 0.5-2
MIC ranges (µg/mL) are according to CLSI M100 26th edition (range for ciprofloxacin and 
ertapenem extended to include 0.016).
Sulfamethoxazole, SMX 8-32
Temocillin, TRM none
Tetracycline, TET 0.5-2
Imipenem, IMI 0.06-0.25
Meropenem, MERO 0.008-0.06
Nalidixic acid, NAL 1-4
Colistin, COL 0.25-2
Ertapenem, ETP 0.004-0.016
Gentamicin, GEN 0.25-1
Ceftazidime + clavulanic acid, T/C none
Chloramphenicol, CHL 2-8
Ciprofloxacin, CIP 0.004-0.016
Cefotaxime + clavulanic acid, F/C none
Cefoxitin, FOX 2-8
Ceftazidime, TAZ 0.06-0.5
Azithromycin, AZI none
Cefepime, FEP 0.015-0.12
Cefotaxime, FOT 0.03-0.12
E. coli ATCC 25922
Antimicrobial MIC
Ampicillin, AMP 2-8
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Test results from the reference strain  E. coli ATCC 25922
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Method Temperature Time
2 1 Ampicillin = 4 2 8 1 MIC 35±1°C 18-24
2 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35±1°C 18-24
2 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35±1°C 18-24
2 1 Chloramphenicol <= 8 2 8 1 MIC 35±1°C 18-24
2 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35±1°C 18-24
2 1 Colistin <= 1  0.25 2 1 MIC 35±1°C 18-24
2 1 Gentamicin <=  0.5  0.25 1 1 MIC 35±1°C 18-24
2 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35±1°C 18-24
2 1 Nalidixic acid <= 4 1 4 1 MIC 35±1°C 18-24
2 1 Sulfamethoxazole = 32 8 32 1 MIC 35±1°C 18-24
2 1 Tetracycline <= 2  0.5 2 1 MIC 35±1°C 18-24
2 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35±1°C 18-24
2 1 Trimethoprim = 1  0.5 2 1 MIC 35±1°C 18-24
2 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35±1°C 18-24
2 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35±1°C 18-24
2 2 Cefoxitin = 8 2 8 1 MIC 35±1°C 18-24
2 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35±1°C 18-24
2 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35±1°C 18-24
2 2 Imipenem =  0.25  0.06  0.25 1 MIC 35±1°C 18-24
2 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35±1°C 18-24
4 1 Ampicillin = 4 2 8 1 MIC 37°C 24h
4 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37°C 24h
4 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37°C 24h
4 1 Chloramphenicol <= 8 2 8 1 MIC 37°C 24h
4 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37°C 24h
4 1 Colistin <= 1  0.25 2 1 MIC 37°C 24h
4 1 Gentamicin <=  0.5  0.25 1 1 MIC 37°C 24h
4 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37°C 24h
4 1 Nalidixic acid <= 4 1 4 1 MIC 37°C 24h
4 1 Sulfamethoxazole = 64 8 32 0 MIC 37°C 24h
4 1 Tetracycline <= 2  0.5 2 1 MIC 37°C 24h
4 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37°C 24h
4 1 Trimethoprim =  0.5  0.5 2 1 MIC 37°C 24h
4 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37°C 24h
4 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37°C 24h
4 2 Cefoxitin = 4 2 8 1 MIC 37°C 24h
4 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37°C 24h
4 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37°C 24h
4 2 Imipenem =  0.25  0.06  0.25 1 MIC 37°C 24h
4 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37°C 24h
6 1 Ampicillin = 8 2 8 1 MIC 35 20
6 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
6 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 20
6 1 Chloramphenicol <= 8 2 8 1 MIC 35 20
6 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 20
6 1 Colistin <= 1  0.25 2 1 MIC 35 20
6 1 Gentamicin = 1  0.25 1 1 MIC 35 20
6 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
6 1 Nalidixic acid <= 4 1 4 1 MIC 35 20
6 1 Sulfamethoxazole = 32 8 32 1 MIC 35 20
6 1 Tetracycline <= 2  0.5 2 1 MIC 35 20
6 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 20
6 1 Trimethoprim = 1  0.5 2 1 MIC 35 20
6 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 20
6 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
6 2 Cefoxitin = 4 2 8 1 MIC 35 20
6 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 20
6 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 20
6 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 20
6 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
9 1 Ampicillin = 4 2 8 1 MIC 35+-2 20
9 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35+-2 20
9 1 Chloramphenicol <= 8 2 8 1 MIC 35+-2 20
9 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35+-2 20
9 1 Colistin <= 1  0.25 2 1 MIC 35+-2 20
9 1 Gentamicin <=  0.5  0.25 1 1 MIC 35+-2 20
9 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35+-2 20
9 1 Nalidixic acid <= 4 1 4 1 MIC 35+-2 20
9 1 Sulfamethoxazole = 16 8 32 1 MIC 35+-2 20
9 1 Tetracycline <= 2  0.5 2 1 MIC 35+-2 20
9 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35+-2 20
9 1 Trimethoprim = 1  0.5 2 1 MIC 35+-2 20
9 2 Cefepime =  0.06  0.015  0.12 1 MIC 35+-2 20
9 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35+-2 20
9 2 Cefoxitin = 4 2 8 1 MIC 35+-2 20
9 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35+-2 20
Appendix 6a, page 2 of 8
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Method Temperature Time
9 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35+-2 20
9 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35+-2 20
9 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35+-2 20
11 1 Ampicillin = 1 2 8 0 MIC 37 24
11 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 24
11 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 24
11 1 Chloramphenicol <= 8 2 8 1 MIC 37 24
11 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 24
11 1 Colistin <= 1  0.25 2 1 MIC 37 24
11 1 Gentamicin <=  0.5  0.25 1 1 MIC 37 24
11 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37 24
11 1 Nalidixic acid <= 4 1 4 1 MIC 37 24
11 1 Sulfamethoxazole <= 8 8 32 1 MIC 37 24
11 1 Tetracycline <= 2  0.5 2 1 MIC 37 24
11 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 24
11 1 Trimethoprim =  0.5  0.5 2 1 MIC 37 24
11 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 24
11 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 24
11 2 Cefoxitin = 4 2 8 1 MIC 37 24
11 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37 24
11 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 24
11 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 24
11 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37 24
12 1 Ampicillin = 4 2 8 1 MIC 35 18-20
12 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-20
12 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 18-20
12 1 Chloramphenicol <= 8 2 8 1 MIC 35 18-20
12 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 18-20
12 1 Colistin <= 1  0.25 2 1 MIC 35 18-20
12 1 Gentamicin = 1  0.25 1 1 MIC 35 18-20
12 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-20
12 1 Nalidixic acid <= 4 1 4 1 MIC 35 18-20
12 1 Sulfamethoxazole = 16 8 32 1 MIC 35 18-20
12 1 Tetracycline <= 2  0.5 2 1 MIC 35 18-20
12 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 18-20
12 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 18-20
12 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 18-20
12 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-20
12 2 Cefoxitin = 4 2 8 1 MIC 35 18-20
12 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 18-20
12 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 18-20
12 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 18-20
12 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-20
16 1 Ampicillin = 4 2 8 1 MIC 35 18-24
16 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-24
16 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 18-24
16 1 Chloramphenicol <= 8 2 8 1 MIC 35 18-24
16 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 18-24
16 1 Colistin <= 1  0.25 2 1 MIC 35 18-24
16 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 18-24
16 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-24
16 1 Nalidixic acid <= 4 1 4 1 MIC 35 18-24
16 1 Sulfamethoxazole = 32 8 32 1 MIC 35 18-24
16 1 Tetracycline <= 2  0.5 2 1 MIC 35 18-24
16 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 18-24
16 1 Trimethoprim = 1  0.5 2 1 MIC 35 18-24
16 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 18-24
16 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-24
16 2 Cefoxitin = 4 2 8 1 MIC 35 18-24
16 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 18-24
16 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 18-24
16 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 18-24
16 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-24
17 1 Ampicillin = 8 2 8 1 MIC 37 20
17 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 20
17 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 20
17 1 Chloramphenicol <= 8 2 8 1 MIC 37 20
17 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 20
17 1 Colistin <= 1  0.25 2 1 MIC 37 20
17 1 Gentamicin <=  0.5  0.25 1 1 MIC 37 20
17 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37 20
17 1 Nalidixic acid <= 4 1 4 1 MIC 37 20
17 1 Sulfamethoxazole = 16 8 32 1 MIC 37 20
17 1 Tetracycline <= 2  0.5 2 1 MIC 37 20
17 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 20
17 1 Trimethoprim =  0.5  0.5 2 1 MIC 37 20
17 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 20
17 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 20
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17 2 Cefoxitin = 4 2 8 1 MIC 37 20
17 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37 20
17 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 20
17 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 20
17 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37 20
18 1 Ampicillin = 2 2 8 1 MIC 37 18
18 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 18
18 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 18
18 1 Chloramphenicol <= 8 2 8 1 MIC 37 18
18 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 18
18 1 Colistin <= 1  0.25 2 1 MIC 37 18
18 1 Gentamicin <=  0.5  0.25 1 1 MIC 37 18
18 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37 18
18 1 Nalidixic acid <= 4 1 4 1 MIC 37 18
18 1 Sulfamethoxazole = 16 8 32 1 MIC 37 18
18 1 Tetracycline <= 2  0.5 2 1 MIC 37 18
18 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 18
18 1 Trimethoprim = 1  0.5 2 1 MIC 37 18
18 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 18
18 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 18
18 2 Cefoxitin = 2 2 8 1 MIC 37 18
18 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37 18
18 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 18
18 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 18
18 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37 18
19 1 Ampicillin = 4 2 8 1 MIC 35 18
19 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18
19 1 Ceftazidime =  0.5  0.06  0.5 1 MIC 35 18
19 1 Chloramphenicol <= 8 2 8 1 MIC 35 18
19 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 18
19 1 Colistin <= 1  0.25 2 1 MIC 35 18
19 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 18
19 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18
19 1 Nalidixic acid <= 4 1 4 1 MIC 35 18
19 1 Sulfamethoxazole = 16 8 32 1 MIC 35 18
19 1 Tetracycline <= 2  0.5 2 1 MIC 35 18
19 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 18
19 1 Trimethoprim <=  0.5  0.5 2 1 MIC 35 18
19 2 Cefepime =  0.12  0.015  0.12 1 MIC 35 18
19 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18
19 2 Cefoxitin = 4 2 8 1 MIC 35 18
19 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 18
19 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 18
19 2 Imipenem =  0.25  0.06  0.25 1 MIC 35 18
19 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18
20 1 Ampicillin = 4 2 8 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Chloramphenicol <= 8 2 8 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Colistin <= 1  0.25 2 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Gentamicin <=  0.5  0.25 1 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Nalidixic acid <= 4 1 4 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Sulfamethoxazole = 16 8 32 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Tetracycline <= 2  0.5 2 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37C +/-1h 20 +/- 2 h
20 1 Trimethoprim =  0.5  0.5 2 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Cefoxitin = 4 2 8 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37C +/-1h 20 +/- 2 h
20 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37C +/-1h 20 +/- 2 h
21 1 Ampicillin = 2 2 8 1 MIC 35 20h
21 1 Cefotaxime =  0.25  0.03  0.12 0 MIC 35 20h
21 1 Ceftazidime =  0.5  0.06  0.5 1 MIC 35 20h
21 1 Chloramphenicol = 8 2 8 1 MIC 35 20h
21 1 Ciprofloxacin =  0.015  0.004  0.016 1 MIC 35 20h
21 1 Colistin = 1  0.25 2 1 MIC 35 20h
21 1 Gentamicin =  0.5  0.25 1 1 MIC 35 20h
21 1 Meropenem =  0.03  0.008  0.06 1 MIC 35 20h
21 1 Nalidixic acid = 4 1 4 1 MIC 35 20h
21 1 Sulfamethoxazole = 8 8 32 1 MIC 35 20h
21 1 Tetracycline = 2  0.5 2 1 MIC 35 20h
21 1 Tigecycline =  0.25  0.03  0.25 1 MIC 35 20h
21 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 20h
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22 1 Ampicillin = 2 2 8 1 MIC 36 20
22 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 36 20
22 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 36 20
22 1 Chloramphenicol <= 8 2 8 1 MIC 36 20
22 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 36 20
22 1 Colistin <= 1  0.25 2 1 MIC 36 20
22 1 Gentamicin = 1  0.25 1 1 MIC 36 20
22 1 Meropenem <=  0.03  0.008  0.06 1 MIC 36 20
22 1 Nalidixic acid <= 4 1 4 1 MIC 36 20
22 1 Tetracycline <= 2  0.5 2 1 MIC 36 20
22 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 36 20
22 1 Trimethoprim =  0.5  0.5 2 1 MIC 36 20
22 2 Cefepime <=  0.06  0.015  0.12 1 MIC 36 20
22 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 36 20
22 2 Cefoxitin = 2 2 8 1 MIC 36 20
22 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 36 20
22 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 36 20
22 2 Imipenem <=  0.12  0.06  0.25 1 MIC 36 20
22 2 Meropenem <=  0.03  0.008  0.06 1 MIC 36 20
23 1 Ampicillin = 4 2 8 1 - - -
23 1 Cefotaxime <=  0.25  0.03  0.12 1 - - -
23 1 Ceftazidime <=  0.5  0.06  0.5 1 - - -
23 1 Chloramphenicol <= 8 2 8 1 - - -
23 1 Ciprofloxacin <=  0.015  0.004  0.016 1 - - -
23 1 Colistin <= 1  0.25 2 1 - - -
23 1 Gentamicin = 1  0.25 1 1 - - -
23 1 Meropenem <=  0.03  0.008  0.06 1 - - -
23 1 Nalidixic acid <= 4 1 4 1 - - -
23 1 Sulfamethoxazole = 16 8 32 1 - - -
23 1 Tetracycline <= 2  0.5 2 1 - - -
23 1 Tigecycline <=  0.25  0.03  0.25 1 - - -
23 1 Trimethoprim =  0.5  0.5 2 1 - - -
23 2 Cefepime <=  0.06  0.015  0.12 1 - - -
23 2 Cefotaxime <=  0.25  0.03  0.12 1 - - -
23 2 Cefoxitin = 2 2 8 1 - - -
23 2 Ceftazidime <=  0.25  0.06  0.5 1 - - -
23 2 Ertapenem <=  0.015  0.004  0.016 1 - - -
23 2 Imipenem <=  0.12  0.06  0.25 1 - - -
23 2 Meropenem <=  0.03  0.008  0.06 1 - - -
25 1 Ampicillin = 4 2 8 1 MIC 35 16 - 20
25 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 16 - 20
25 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 16 - 20
25 1 Chloramphenicol <= 8 2 8 1 MIC 35 16 - 20
25 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 16 - 20
25 1 Colistin <= 1  0.25 2 1 MIC 35 16 - 20
25 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 16 - 20
25 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 16 - 20
25 1 Nalidixic acid <= 4 1 4 1 MIC 35 16 - 20
25 1 Sulfamethoxazole <= 8 8 32 1 MIC 35 16 - 20
25 1 Tetracycline <= 2  0.5 2 1 MIC 35 16 - 20
25 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 16 - 20
25 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 16 - 20
25 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 16 - 20
25 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 16 - 20
25 2 Cefoxitin = 4 2 8 1 MIC 35 16 - 20
25 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 16 - 20
25 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 16 - 20
25 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 16 - 20
25 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 16 - 20
26 1 Ampicillin = 4 2 8 1 MIC 37 18
26 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 18
26 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 18
26 1 Chloramphenicol <= 8 2 8 1 MIC 37 18
26 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 18
26 1 Colistin <= 1  0.25 2 1 MIC 37 18
26 1 Gentamicin = 1  0.25 1 1 MIC 37 18
26 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37 18
26 1 Nalidixic acid <= 4 1 4 1 MIC 37 18
26 1 Sulfamethoxazole = 16 8 32 1 MIC 37 18
26 1 Tetracycline <= 2  0.5 2 1 MIC 37 18
26 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 18
26 1 Trimethoprim =  0.5  0.5 2 1 MIC 37 18
26 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 18
26 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 18
26 2 Cefoxitin = 8 2 8 1 MIC 37 18
26 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37 18
26 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 18
26 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 18
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26 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37 18
29 1 Ampicillin = 4 2 8 1 MIC 37 18-24
29 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 18-24
29 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 18-24
29 1 Chloramphenicol <= 8 2 8 1 MIC 37 18-24
29 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 18-24
29 1 Colistin = 1  0.25 2 1 MIC 37 18-24
29 1 Gentamicin =  0.25  0.25 1 1 MIC 37 18-24
29 1 Meropenem =  0.06  0.008  0.06 1 MIC 37 18-24
29 1 Nalidixic acid <= 4 1 4 1 MIC 37 18-24
29 1 Sulfamethoxazole = 8 8 32 1 MIC 37 18-24
29 1 Tetracycline = 1  0.5 2 1 MIC 37 18-24
29 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 18-24
29 1 Trimethoprim = 1  0.5 2 1 MIC 37 18-24
29 2 Cefepime =  0.12  0.015  0.12 1 MIC 37 18-24
29 2 Cefoxitin = 2 2 8 1 MIC 37 18-24
29 2 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 18-24
29 2 Ertapenem <=  0.15  0.004  0.016 1 MIC 37 18-24
29 2 Imipenem =  0.25  0.06  0.25 1 MIC 37 18-24
29 2 Meropenem =  0.06  0.008  0.06 1 MIC 37 18-24
30 1 Ampicillin = 4 2 8 1 MIC 35 20
30 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
30 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 20
30 1 Chloramphenicol <= 8 2 8 1 MIC 35 20
30 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 20
30 1 Colistin <= 1  0.25 2 1 MIC 35 20
30 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 20
30 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
30 1 Nalidixic acid <= 4 1 4 1 MIC 35 20
30 1 Sulfamethoxazole <= 8 8 32 1 MIC 35 20
30 1 Tetracycline <= 2  0.5 2 1 MIC 35 20
30 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 20
30 1 Trimethoprim <=  0.25  0.5 2 0 MIC 35 20
30 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 20
30 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
30 2 Cefoxitin = 2 2 8 1 MIC 35 20
30 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 20
30 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 20
30 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 20
30 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
32 1 Ampicillin = 4 2 8 1 MIC 37+-1 -
32 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37+-1 -
32 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37+-1 -
32 1 Chloramphenicol <= 8 2 8 1 MIC 37+-1 -
32 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37+-1 -
32 1 Colistin <= 1  0.25 2 1 MIC 37+-1 -
32 1 Gentamicin <=  0.5  0.25 1 1 MIC 37+-1 -
32 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37+-1 -
32 1 Nalidixic acid <= 4 1 4 1 MIC 37+-1 -
32 1 Sulfamethoxazole = 16 8 32 1 MIC 37+-1 -
32 1 Tetracycline <= 2  0.5 2 1 MIC 37+-1 -
32 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37+-1 -
32 1 Trimethoprim =  0.5  0.5 2 1 MIC 37+-1 -
32 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37+-1 -
32 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37+-1 -
32 2 Cefoxitin = 4 2 8 1 MIC 37+-1 -
32 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37+-1 -
32 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37+-1 -
32 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37+-1 -
32 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37+-1 -
33 1 Ampicillin = 4 2 8 1 MIC 35 18
33 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18
33 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 18
33 1 Chloramphenicol <= 8 2 8 1 MIC 35 18
33 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 18
33 1 Colistin <= 1  0.25 2 1 MIC 35 18
33 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 18
33 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18
33 1 Nalidixic acid <= 4 1 4 1 MIC 35 18
33 1 Sulfamethoxazole = 32 8 32 1 MIC 35 18
33 1 Tetracycline <= 2  0.5 2 1 MIC 35 18
33 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 18
33 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 18
33 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 18
33 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18
33 2 Cefoxitin = 4 2 8 1 MIC 35 18
33 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 18
33 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 18
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33 2 Imipenem =  0.25  0.06  0.25 1 MIC 35 18
33 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18
34 1 Ampicillin = 4 2 8 1 - - -
34 1 Cefotaxime <=  0.25  0.03  0.12 1 - - -
34 1 Ceftazidime <=  0.5  0.06  0.5 1 - - -
34 1 Chloramphenicol <= 8 2 8 1 - - -
34 1 Ciprofloxacin <=  0.015  0.004  0.016 1 - - -
34 1 Colistin <= 1  0.25 2 1 - - -
34 1 Gentamicin <=  0.5  0.25 1 1 - - -
34 1 Meropenem <=  0.03  0.008  0.06 1 - - -
34 1 Nalidixic acid <= 4 1 4 1 - - -
34 1 Sulfamethoxazole <= 8 8 32 1 - - -
34 1 Tetracycline <= 2  0.5 2 1 - - -
34 1 Tigecycline <=  0.25  0.03  0.25 1 - - -
34 1 Trimethoprim =  0.5  0.5 2 1 - - -
34 2 Cefepime <=  0.06  0.015  0.12 1 - - -
34 2 Cefotaxime <=  0.25  0.03  0.12 1 - - -
34 2 Cefoxitin = 2 2 8 1 - - -
34 2 Ceftazidime <=  0.25  0.06  0.5 1 - - -
34 2 Ertapenem <=  0.015  0.004  0.016 1 - - -
34 2 Imipenem <=  0.12  0.06  0.25 1 - - -
34 2 Meropenem <=  0.03  0.008  0.06 1 - - -
36 1 Ampicillin = 4 2 8 1 MIC 35 18-24
36 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-24
36 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 18-24
36 1 Chloramphenicol <= 8 2 8 1 MIC 35 18-24
36 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 18-24
36 1 Colistin <= 1  0.25 2 1 MIC 35 18-24
36 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 18-24
36 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-24
36 1 Nalidixic acid <= 4 1 4 1 MIC 35 18-24
36 1 Sulfamethoxazole <= 8 8 32 1 MIC 35 18-24
36 1 Tetracycline <= 2  0.5 2 1 MIC 35 18-24
36 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 18-24
36 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 18-24
36 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 18-24
36 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 18-24
36 2 Cefoxitin = 4 2 8 1 MIC 35 18-24
36 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 18-24
36 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 18-24
36 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 18-24
36 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 18-24
37 1 Ampicillin = 8 2 8 1 AGA 37ºC 18-24 hrs
37 1 Cefotaxime <=  0.25  0.03  0.12 1 AGA 37ºC 18-24 hrs
37 1 Ceftazidime <=  0.5  0.06  0.5 1 AGA 37ºC 18-24 hrs
37 1 Chloramphenicol <= 8 2 8 1 AGA 37ºC 18-24 hrs
37 1 Ciprofloxacin <=  0.015  0.004  0.016 1 AGA 37ºC 18-24 hrs
37 1 Colistin <= 1  0.25 2 1 AGA 37ºC 18-24 hrs
37 1 Gentamicin <=  0.5  0.25 1 1 AGA 37ºC 18-24 hrs
37 1 Meropenem <=  0.03  0.008  0.06 1 AGA 37ºC 18-24 hrs
37 1 Nalidixic acid <= 4 1 4 1 AGA 37ºC 18-24 hrs
37 1 Sulfamethoxazole = 16 8 32 1 AGA 37ºC 18-24 hrs
37 1 Tetracycline <= 2  0.5 2 1 AGA 37ºC 18-24 hrs
37 1 Tigecycline <=  0.25  0.03  0.25 1 AGA 37ºC 18-24 hrs
37 1 Trimethoprim =  0.5  0.5 2 1 AGA 37ºC 18-24 hrs
37 2 Cefepime =  0.015  0.015  0.12 1 AGA 37ºC 18-24 hrs
37 2 Cefotaxime <=  0.25  0.03  0.12 1 AGA 37ºC 18-24 hrs
37 2 Cefoxitin = 4 2 8 1 AGA 37ºC 18-24 hrs
37 2 Ceftazidime <=  0.5  0.06  0.5 1 AGA 37ºC 18-24 hrs
37 2 Ertapenem <=  0.015  0.004  0.016 1 AGA 37ºC 18-24 hrs
37 2 Imipenem =  0.125  0.06  0.25 1 AGA 37ºC 18-24 hrs
37 2 Meropenem <=  0.03  0.008  0.06 1 AGA 37ºC 18-24 hrs
39 1 Ampicillin = 4 2 8 1 MIC 37 24
39 1 Cefotaxime =  0.06  0.03  0.12 1 MIC 37 24
39 1 Ceftazidime =  0.5  0.06  0.5 1 MIC 37 24
39 1 Chloramphenicol = 4 2 8 1 MIC 37 24
39 1 Ciprofloxacin =  0.016  0.004  0.016 1 MIC 37 24
39 1 Colistin =  0.5  0.25 2 1 MIC 37 24
39 1 Gentamicin =  0.5  0.25 1 1 MIC 37 24
39 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37 24
39 1 Nalidixic acid = 2 1 4 1 MIC 37 24
39 1 Sulfamethoxazole = 16 8 32 1 MIC 37 24
39 1 Tetracycline <= 1  0.5 2 1 MIC 37 24
39 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 24
39 1 Trimethoprim = 1  0.5 2 1 MIC 37 24
39 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 24
39 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 24
39 2 Cefoxitin = 4 2 8 1 MIC 37 24
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39 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37 24
39 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 24
39 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 24
39 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37 24
40 1 Ampicillin = 2 2 8 1 MIC 37 18
40 1 Cefotaxime =  0.12  0.03  0.12 1 MIC 37 18
40 1 Ceftazidime =  0.5  0.06  0.5 1 MIC 37 18
40 1 Chloramphenicol = 8 2 8 1 MIC 37 18
40 1 Ciprofloxacin =  0.015  0.004  0.016 1 MIC 37 18
40 1 Colistin = 1  0.25 2 1 MIC 37 18
40 1 Gentamicin =  0.5  0.25 1 1 MIC 37 18
40 1 Meropenem =  0.03  0.008  0.06 1 MIC 37 18
40 1 Nalidixic acid = 4 1 4 1 MIC 37 18
40 1 Sulfamethoxazole = 16 8 32 1 MIC 37 18
40 1 Tetracycline = 2  0.5 2 1 MIC 37 18
40 1 Tigecycline =  0.25  0.03  0.25 1 MIC 37 18
40 1 Trimethoprim =  0.25  0.5 2 0 MIC 37 18
40 2 Cefepime =  0.06  0.015  0.12 1 MIC 37 18
40 2 Cefotaxime =  0.25  0.03  0.12 0 MIC 37 18
40 2 Cefoxitin = 2 2 8 1 MIC 37 18
40 2 Ceftazidime =  0.5  0.06  0.5 1 MIC 37 18
40 2 Ertapenem =  0.015  0.004  0.016 1 MIC 37 18
40 2 Imipenem =  0.12  0.06  0.25 1 MIC 37 18
40 2 Meropenem =  0.03  0.008  0.06 1 MIC 37 18
41 1 Ampicillin = 4 2 8 1 MIC 37 24
41 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 24
41 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 24
41 1 Chloramphenicol <= 8 2 8 1 MIC 37 24
41 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37 24
41 1 Colistin = 2  0.25 2 1 MIC 37 24
41 1 Gentamicin = 1  0.25 1 1 MIC 37 24
41 1 Meropenem =  0.06  0.008  0.06 1 MIC 37 24
41 1 Nalidixic acid <= 4 1 4 1 MIC 37 24
41 1 Sulfamethoxazole = 16 8 32 1 MIC 37 24
41 1 Tetracycline <= 2  0.5 2 1 MIC 37 24
41 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37 24
41 1 Trimethoprim =  0.5  0.5 2 1 MIC 37 24
41 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37 24
41 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37 24
41 2 Cefoxitin = 2 2 8 1 MIC 37 24
41 2 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37 24
41 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37 24
41 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37 24
41 2 Meropenem <=  0.06  0.008  0.06 1 MIC 37 24
42 1 Ampicillin = 8 2 8 1 MIC 37°C 24 h
42 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37°C 24 h
42 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 37°C 24 h
42 1 Chloramphenicol <= 8 2 8 1 MIC 37°C 24 h
42 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 37°C 24 h
42 1 Colistin <= 1  0.25 2 1 MIC 37°C 24 h
42 1 Gentamicin <=  0.5  0.25 1 1 MIC 37°C 24 h
42 1 Meropenem <=  0.03  0.008  0.06 1 MIC 37°C 24 h
42 1 Nalidixic acid <= 4 1 4 1 MIC 37°C 24 h
42 1 Sulfamethoxazole = 32 8 32 1 MIC 37°C 24 h
42 1 Tetracycline <= 2  0.5 2 1 MIC 37°C 24 h
42 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 37°C 24 h
42 1 Trimethoprim = 1  0.5 2 1 MIC 37°C 24 h
42 2 Cefepime <=  0.06  0.015  0.12 1 MIC 37°C 24 h
42 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 37°C 24 h
42 2 Cefoxitin = 4 2 8 1 MIC 37°C 24 h
42 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 37°C 24 h
42 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 37°C 24 h
42 2 Imipenem <=  0.12  0.06  0.25 1 MIC 37°C 24 h
42 2 Meropenem <=  0.03  0.008  0.06 1 MIC 37°C 24 h
45 1 Ampicillin = 4 2 8 1 MIC 36 20
45 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 36 20
45 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 36 20
45 1 Chloramphenicol <= 8 2 8 1 MIC 36 20
45 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 36 20
45 1 Colistin <= 1  0.25 2 1 MIC 36 20
45 1 Gentamicin <=  0.15  0.25 1 0 MIC 36 20
45 1 Meropenem <=  0.03  0.008  0.06 1 MIC 36 20
45 1 Nalidixic acid <= 4 1 4 1 MIC 36 20
45 1 Sulfamethoxazole = 16 8 32 1 MIC 36 20
45 1 Tetracycline <= 2  0.5 2 1 MIC 36 20
45 1 Tigecycline =  0.5  0.03  0.25 0 MIC 36 20
45 1 Trimethoprim =  0.5  0.5 2 1 MIC 36 20
45 2 Cefepime <=  0.06  0.015  0.12 1 MIC 36 20
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45 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 36 20
45 2 Cefoxitin = 4 2 8 1 MIC 36 20
45 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 36 20
45 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 36 20
45 2 Imipenem =  0.25  0.06  0.25 1 MIC 36 20
45 2 Meropenem <=  0.03  0.008  0.06 1 MIC 36 20
56 1 Ampicillin = 4 2 8 1 MIC 35 20
56 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
56 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 20
56 1 Chloramphenicol <= 8 2 8 1 MIC 35 20
56 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 20
56 1 Colistin <= 1  0.25 2 1 MIC 35 20
56 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 20
56 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
56 1 Nalidixic acid <= 4 1 4 1 MIC 35 20
56 1 Sulfamethoxazole = 32 8 32 1 MIC 35 20
56 1 Tetracycline <= 2  0.5 2 1 MIC 35 20
56 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 20
56 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 20
56 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 20
56 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 20
56 2 Cefoxitin = 4 2 8 1 MIC 35 20
56 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 20
56 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 20
56 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 20
56 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 20
59 1 Ampicillin = 4 2 8 1 MIC 35 24
59 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 24
59 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35 24
59 1 Chloramphenicol <= 8 2 8 1 MIC 35 24
59 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35 24
59 1 Colistin <= 1  0.25 2 1 MIC 35 24
59 1 Gentamicin <=  0.5  0.25 1 1 MIC 35 24
59 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35 24
59 1 Nalidixic acid <= 4 1 4 1 MIC 35 24
59 1 Sulfamethoxazole = 64 8 32 0 MIC 35 24
59 1 Tetracycline <= 2  0.5 2 1 MIC 35 24
59 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35 24
59 1 Trimethoprim =  0.5  0.5 2 1 MIC 35 24
59 2 Cefepime <=  0.06  0.015  0.12 1 MIC 35 24
59 2 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35 24
59 2 Cefoxitin = 2 2 8 1 MIC 35 24
59 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC 35 24
59 2 Ertapenem <=  0.015  0.004  0.016 1 MIC 35 24
59 2 Imipenem <=  0.12  0.06  0.25 1 MIC 35 24
59 2 Meropenem <=  0.03  0.008  0.06 1 MIC 35 24
60 1 Ampicillin = 4 2 8 1 MIC 35-37 18-20
60 1 Cefotaxime <=  0.25  0.03  0.12 1 MIC 35-37 18-20
60 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC 35-37 18-20
60 1 Chloramphenicol <= 8 2 8 1 MIC 35-37 18-20
60 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC 35-37 18-20
60 1 Colistin <= 1  0.25 2 1 MIC 35-37 18-20
60 1 Gentamicin <=  0.5  0.25 1 1 MIC 35-37 18-20
60 1 Meropenem <=  0.03  0.008  0.06 1 MIC 35-37 18-20
60 1 Nalidixic acid <= 4 1 4 1 MIC 35-37 18-20
60 1 Sulfamethoxazole <= 8 8 32 1 MIC 35-37 18-20
60 1 Tetracycline <= 2  0.5 2 1 MIC 35-37 18-20
60 1 Tigecycline <=  0.25  0.03  0.25 1 MIC 35-37 18-20
60 1 Trimethoprim <=  0.25  0.5 2 0 MIC 35-37 18-20
MIC: Microbroth dilution
AGA: Agar dilution
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Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
2 Ciprofloxacin = 0.12 0.06 0.25 MIC 1 X
2 Erythromycin = 0.5 0.5 2 MIC 1 X
2 Gentamicin <= 0.12 0.5 2 MIC 0 X
2 Nalidixic acid = 4 4 16 MIC 1 X
2 Tetracycline = 1 0.25 2 MIC 1 X
4 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
4 Erythromycin = 2 0.5 2 MIC 1 X
4 Gentamicin = 0.5 0.5 2 MIC 1 X
4 Nalidixic acid = 8 4 16 MIC 1 X
4 Tetracycline = 2 0.25 2 MIC 1 X
6 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
6 Erythromycin <= 1 0.25 2 MIC 1 X
6 Gentamicin = 1 0.25 2 MIC 1 X
6 Nalidixic acid = 4 4 16 MIC 1 X
6 Tetracycline <= 0.5 0.25 1 MIC 1 X
9 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
9 Erythromycin <= 1 0.5 2 MIC 1 X
9 Gentamicin = 1 0.5 2 MIC 1 X
9 Nalidixic acid = 8 4 16 MIC 1 X
9 Tetracycline = 1 0.25 2 MIC 1 X
11 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
11 Erythromycin <= 1 0.5 2 MIC 1 X
11 Gentamicin = 1 0.5 2 MIC 1 X
11 Nalidixic acid = 8 4 16 MIC 1 X
11 Tetracycline = 1 0.25 2 MIC 1 X
12 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
12 Erythromycin <= 1 0.5 2 MIC 1 X
12 Gentamicin = 1 0.5 2 MIC 1 X
12 Nalidixic acid = 8 4 16 MIC 1 X
12 Tetracycline = 1 0.25 2 MIC 1 X
14 Ciprofloxacin <= 0.125 0.03 0.125 MIC 1 X
14 Erythromycin <= 1 0.25 2 MIC 1 X
14 Gentamicin = 0.5 0.25 2 MIC 1 X
14 Nalidixic acid = 4 4 16 MIC 1 X
14 Tetracycline = 1 0.25 1 MIC 1 X
17 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
17 Erythromycin = 2 0.5 2 MIC 1 X
17 Gentamicin = 1 0.5 2 MIC 1 X
17 Nalidixic acid = 8 4 16 MIC 1 X
17 Tetracycline <= 0.5 0.25 2 MIC 1 X
18 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
18 Erythromycin <= 1 0.25 2 MIC 1 X
18 Gentamicin = 0.25 0.25 2 MIC 1 X
18 Nalidixic acid = 8 4 16 MIC 1 X
18 Tetracycline <= 0.5 0.25 1 MIC 1 X
19 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
19 Erythromycin <= 1 0.25 2 MIC 1 X
19 Gentamicin = 0.5 0.25 2 MIC 1 X
19 Nalidixic acid = 4 4 16 MIC 1 X
19 Tetracycline <= 0.5 0.25 1 MIC 1 X
20 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
20 Erythromycin <= 1 0.5 2 MIC 1 X
20 Gentamicin = 1 0.5 2 MIC 1 X
20 Nalidixic acid = 8 4 16 MIC 1 X
20 Tetracycline = 4 0.25 2 MIC 0 X
21 Ciprofloxacin = 0.12 0.03 0.125 MIC 1 X
21 Erythromycin = 1 0.25 2 MIC 1 X
21 Gentamicin = 0.25 0.25 2 MIC 1 X
21 Nalidixic acid = 4 4 16 MIC 1 X
21 Tetracycline = 0.5 0.25 1 MIC 1 X
22 Ciprofloxacin <= 0.06 0.03 0.125 MIC 1 X
22 Erythromycin <= 1 0.25 2 MIC 1 X
22 Nalidixic acid = 4 4 16 MIC 1 X
22 Tetracycline = 1 0.25 1 MIC 1 X
25 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
25 Erythromycin = 2 0.5 2 MIC 1 X
25 Gentamicin = 0.25 0.5 2 MIC 0 X
25 Nalidixic acid = 8 4 16 MIC 1 X
25 Tetracycline = 2 0.25 2 MIC 1 X
26 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
26 Erythromycin <= 1 0.5 2 MIC 1 X
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26 Gentamicin = 1 0.5 2 MIC 1 X
26 Nalidixic acid = 8 4 16 MIC 1 X
26 Tetracycline = 1 0.25 2 MIC 1 X
29 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
29 Erythromycin = 2 0.5 2 MIC 1 X
29 Gentamicin = 1 0.5 2 MIC 1 X
29 Nalidixic acid = 8 4 16 MIC 1 X
29 Tetracycline = 1 0.25 2 MIC 1 X
30 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
30 Erythromycin <= 1 0.5 2 MIC 1 X
30 Gentamicin = 0.5 0.5 2 MIC 1 X
30 Nalidixic acid = 8 4 16 MIC 1 X
30 Tetracycline <= 0.5 0.25 2 MIC 1 X
32 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
32 Erythromycin <= 1 0.5 2 MIC 1 X
32 Gentamicin = 1 0.5 2 MIC 1 X
32 Nalidixic acid = 8 4 16 MIC 1 X
32 Tetracycline = 1 0.25 2 MIC 1 X
33 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
33 Erythromycin <= 1 0.5 2 MIC 1 X
33 Gentamicin = 0.5 0.5 2 MIC 1 X
33 Nalidixic acid = 8 4 16 MIC 1 X
33 Tetracycline = 1 0.25 2 MIC 1 X
36 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
36 Erythromycin <= 1 0.25 2 MIC 1 X
36 Gentamicin = 0.5 0.25 2 MIC 1 X
36 Nalidixic acid = 4 4 16 MIC 1 X
36 Tetracycline <= 0.5 0.25 1 MIC 1 X
37 Ciprofloxacin = 0.25 0.12 1 AGA 1 X
37 Erythromycin <= 1 1 8 AGA 1 X
37 Gentamicin = 1 0.5 2 AGA 1 X
39 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
39 Erythromycin <= 1 0.25 2 MIC 1 X
39 Gentamicin = 0.25 0.25 2 MIC 1 X
39 Nalidixic acid = 4 4 16 MIC 1 X
39 Tetracycline <= 0.5 0.25 1 MIC 1 X
40 Ciprofloxacin = 0.12 0.03 0.125 MIC 1 X
40 Erythromycin = 1 0.25 2 MIC 1 X
40 Nalidixic acid = 4 4 16 MIC 1 X
40 Tetracycline = 0.5 0.25 1 MIC 1 X
41 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
41 Erythromycin <= 1 0.25 2 MIC 1 X
41 Gentamicin = 1 0.25 2 MIC 1 X
41 Nalidixic acid = 8 4 16 MIC 1 X
41 Tetracycline = 1 0.25 1 MIC 1 X
42 Ciprofloxacin = 0.25 0.03 0.125 MIC 0 X
42 Erythromycin <= 1 0.25 2 MIC 1 X
42 Nalidixic acid = 8 4 16 MIC 1 X
42 Tetracycline = 2 0.25 1 MIC 0 X
45 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
45 Erythromycin <= 1 0.5 2 MIC 1 X
45 Nalidixic acid = 2 4 16 MIC 0 X
45 Tetracycline <= 0.5 0.25 2 MIC 1 X
56 Ciprofloxacin <= 0.12 0.03 0.125 MIC 1 X
56 Erythromycin <= 1 0.25 2 MIC 1 X
56 Gentamicin = 0.5 0.25 2 MIC 1 X
56 Nalidixic acid = 8 4 16 MIC 1 X
56 Tetracycline = 1 0.25 1 MIC 1 X
59 Ciprofloxacin <= 0.12 0.06 0.25 MIC 1 X
59 Erythromycin <= 1 0.5 2 MIC 1 X
59 Gentamicin = 1 0.5 2 MIC 1 X
59 Nalidixic acid = 8 4 16 MIC 1 X
59 Tetracycline = 1 0.25 2 MIC 1 X
60 Ciprofloxacin = 0.25 0.06 0.25 MIC 1 X
60 Erythromycin <= 1 0.5 2 MIC 1 X
60 Gentamicin = 1 0.5 2 MIC 1 X
60 Nalidixic acid = 8 4 16 MIC 1 X
60 Tetracycline = 1 0.25 2 MIC 1 X
MIC: Microbroth dilution
AGA: Agar dilution
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Panel Expected % R % S No. correct
No. 
incorrect
Ampicillin AMP EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 R 100% 0% 31 0
EURL S-11.3 Panel 1 R 100% 0% 31 0
EURL S-11.4 Panel 1 R 100% 0% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 R 100% 0% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
Azithromycin AZI EURL S-11.1 Panel 1 R 100% 0% 25 0
EURL S-11.2 Panel 1 S 0% 100% 25 0
EURL S-11.3 Panel 1 S 0% 100% 25 0
EURL S-11.4 Panel 1 S 0% 100% 25 0
EURL S-11.5 Panel 1 S 0% 100% 25 0
EURL S-11.6 Panel 1 S 0% 100% 25 0
EURL S-11.7 Panel 1 S 0% 100% 25 0
EURL S-11.8 Panel 1 R 100% 0% 25 0
Cefotaxime FOT EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.1 Panel 2 R 100% 0% 31 0
EURL S-11.2 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 2 R 100% 0% 30 0
EURL S-11.3 Panel 1 R 100% 0% 31 0
EURL S-11.3 Panel 2 R 100% 0% 31 0
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.5 Panel 2 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 R 100% 0% 31 0
EURL S-11.7 Panel 2 R 100% 0% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
EURL S-11.8 Panel 2 R 100% 0% 31 0
Cefoxitin FOX EURL S-11.1 Panel 2 S 13% 87% 27 4
EURL S-11.2 Panel 2 S 0% 100% 30 0
EURL S-11.3 Panel 2 S 3% 97% 30 1
EURL S-11.5* Panel 2 S 71% 29% 9 22
EURL S-11.7 Panel 2 S 0% 100% 31 0
EURL S-11.8 Panel 2 S 0% 100% 31 0
Ceftazidime TAZ EURL S-11.1 Panel 1 S 10% 90% 28 3
EURL S-11.1 Panel 2 S 6% 94% 29 2
EURL S-11.2 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 2 R 100% 0% 30 0
EURL S-11.3 Panel 1 S 6% 94% 29 2
EURL S-11.3 Panel 2 S 10% 90% 28 3
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 94% 6% 29 2
EURL S-11.5 Panel 2 R 94% 6% 29 2
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7* Panel 1 R 43% 57% 13 17
EURL S-11.7* Panel 2 R 47% 53% 14 16
EURL S-11.8 Panel 1 R 100% 0% 31 0
EURL S-11.8 Panel 2 R 100% 0% 31 0
Chloramphenicol CHL EURL S-11.1 Panel 1 S 0% 100% 31 0
EURL S-11.2 Panel 1 R 100% 0% 31 0
EURL S-11.3 Panel 1 S 3% 97% 30 1
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
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Ciprofloxacin CIP EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 R 100% 0% 31 0
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
Colistin COL EURL S-11.1 Panel 1 S 0% 100% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.4 Panel 1 R 97% 3% 30 1
EURL S-11.5 Panel 1 S 0% 100% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 S 0% 100% 31 0
Ertapenem ETP EURL S-11.1 Panel 2 R 100% 0% 31 0
EURL S-11.2 Panel 2 S 0% 100% 30 0
EURL S-11.3 Panel 2 S 0% 100% 31 0
EURL S-11.5 Panel 2 S 0% 100% 31 0
EURL S-11.7 Panel 2 S 0% 100% 31 0
EURL S-11.8 Panel 2 S 6% 94% 29 2
Gentamicin GEN EURL S-11.1 Panel 1 R 97% 3% 30 1
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
Imipenem IMI EURL S-11.1 Panel 2 R 80% 20% 24 6
EURL S-11.2 Panel 2 S 0% 100% 30 0
EURL S-11.3 Panel 2 S 0% 100% 31 0
EURL S-11.5 Panel 2 S 0% 100% 31 0
EURL S-11.7 Panel 2 S 0% 100% 31 0
EURL S-11.8 Panel 2 S 0% 100% 31 0
Meropenem MER EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.1 Panel 2 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.2 Panel 2 S 0% 100% 30 0
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 2 S 0% 100% 31 0
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 2 S 0% 100% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 2 S 0% 100% 31 0
EURL S-11.8 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 2 S 0% 100% 31 0
Nalidixic acid NAL EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 R 100% 0% 31 0
EURL S-11.4 Panel 1 S 0% 100% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
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Sulfamethoxazole SMX EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 3% 97% 30 1
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.4 Panel 1 R 100% 0% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 3% 97% 30 1
EURL S-11.7 Panel 1 R 97% 3% 29 1
EURL S-11.8 Panel 1 R 100% 0% 31 0
Temocillin TRM EURL S-11.1 Panel 2 R 100% 0% 26 0
EURL S-11.2 Panel 2 S 0% 100% 26 0
EURL S-11.3 Panel 2 S 0% 100% 26 0
EURL S-11.5 Panel 2 S 0% 100% 26 0
EURL S-11.7 Panel 2 S 0% 100% 26 0
EURL S-11.8 Panel 2 S 0% 100% 26 0
Tetracycline TET EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 R 100% 0% 31 0
EURL S-11.4 Panel 1 R 100% 0% 31 0
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 R 100% 0% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
Tigecycline TGC EURL S-11.1 Panel 1 S 0% 100% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.4 Panel 1 S 10% 90% 28 3
EURL S-11.5 Panel 1 S 16% 84% 26 5
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 3% 97% 30 1
EURL S-11.8 Panel 1 S 10% 90% 28 3
Trimethoprim TMP EURL S-11.1 Panel 1 R 100% 0% 31 0
EURL S-11.2 Panel 1 S 0% 100% 31 0
EURL S-11.3 Panel 1 S 0% 100% 31 0
EURL S-11.4 Panel 1 R 97% 3% 30 1
EURL S-11.5 Panel 1 R 100% 0% 31 0
EURL S-11.6 Panel 1 S 0% 100% 31 0
EURL S-11.7 Panel 1 S 0% 100% 31 0
EURL S-11.8 Panel 1 R 100% 0% 31 0
*Strain/antimicrobial-combination excluded from the evaluation
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-11.1 S 0 100 31 0
EURL C-11.2 R 100 0 31 0
EURL C-11.3 R 100 0 31 0
EURL C-11.4 R 100 0 31 0
EURL C-11.5 R 94 6 29 2
EURL C-11.6 S 0 100 31 0
EURL C-11.7 R 100 0 31 0
EURL C-11.8 S 0 100 31 0
EURL C-11.1 S 0 100 31 0
EURL C-11.2 R 100 0 31 0
EURL C-11.3 S 0 100 31 0
EURL C-11.4 S 0 100 31 0
EURL C-11.5 S 0 100 31 0
EURL C-11.6 S 0 100 31 0
EURL C-11.7 S 0 100 31 0
EURL C-11.8 S 0 100 31 0
EURL C-11.1 S 0 100 31 0
EURL C-11.2 S 0 100 31 0
EURL C-11.3 S 0 100 31 0
EURL C-11.4 S 0 100 31 0
EURL C-11.5 S 0 100 31 0
EURL C-11.6 S 3 97 30 1
EURL C-11.7 S 0 100 31 0
EURL C-11.8 S 0 100 31 0
EURL C-11.1 S 0 100 31 0
EURL C-11.2 R 100 0 31 0
EURL C-11.3 R 100 0 31 0
EURL C-11.4 R 100 0 31 0
EURL C-11.5 R 97 3 30 1
EURL C-11.6 S 0 100 31 0
EURL C-11.7 R 100 0 31 0
EURL C-11.8 S 0 100 31 0
EURL C-11.1 S 0 100 31 0
EURL C-11.2 S 0 100 31 0
EURL C-11.3 S 0 100 31 0
EURL C-11.4* S 90 10 3 28
EURL C-11.5 S 3 97 30 1
EURL C-11.6 R 100 0 31 0
EURL C-11.7 S 0 100 31 0
EURL C-11.8 S 0 100 31 0
EURL C-11.1 S 0 100 31 0
EURL C-11.2 R 100 0 31 0
EURL C-11.3 R 100 0 31 0
EURL C-11.4 R 100 0 31 0
EURL C-11.5 R 97 3 30 1
EURL C-11.6 S 0 100 31 0
EURL C-11.7 R 100 0 31 0
EURL C-11.8 R 100 0 31 0
*Strain/antimicrobial-combination excluded from the evaluation
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Deviations - Salmonella
Lab no. Strain Panel Antimicrobial Obtained MIC value
Obtained 
interpretation
Expected 
MIC-value
Expected 
interpretation
4 EURL S-11.1 1 Gentamicin GEN 16 S 32 R
4 EURL S-11.1 2 Imipenem IMI 1 S 4 R
4 EURL S-11.8 1 Tigecycline TGC 2 R 1 S
6 EURL S-11.4 1 Tigecycline TGC 2 R 1 S
9 EURL S-11.8 2 Ertapenem ETP  0.06 R 0.06 S
11 EURL S-11.1 1 Ceftazidime TAZ 1 R 1 S
11 EURL S-11.1 2 Ceftazidime TAZ 1 R 1 S
11 EURL S-11.3 1 Ceftazidime TAZ 1 R 1 S
11 EURL S-11.3 2 Ceftazidime TAZ 1 R 1 S
11 EURL S-11.4 1 Tigecycline TGC 2 R 1 S
11 EURL S-11.4 1 Trimethoprim TMP > 32 S > 32 R
11 EURL S-11.5 1 Tigecycline TGC 2 R 1 S
12 EURL S-11.3 1 Chloramphenicol CHL <= 8 R <= 8 S
17 EURL S-11.1 2 Cefoxitin FOX 16 R 8 S
19 EURL S-11.1 2 Imipenem IMI 1 S 4 R
19 EURL S-11.2 ESBL-categorization
20 EURL S-11.1 2 Imipenem IMI 1 S 4 R
21 EURL S-11.1 2 Imipenem IMI = 0.5 S 4 R
21 EURL S-11.5 1 Ceftazidime TAZ 2 S 8 R
21 EURL S-11.5 2 Ceftazidime TAZ 2 S 8 R
21 EURL S-11.7 1 Sulfamethoxazole SMX 2048 S > 1024 R
22 EURL S-11.1 1 Ceftazidime TAZ 1 R 1 S
22 EURL S-11.1 2 Ceftazidime TAZ 1 R 1 S
22 EURL S-11.5 1 Tigecycline TGC 1 R 1 S
22 EURL S-11.8 1 Tigecycline TGC 1 R 1 S
26 EURL S-11.1 1 Ceftazidime TAZ 1 R 1 S
26 EURL S-11.3 2 Ceftazidime TAZ 1 R 1 S
29 EURL S-11.1 2 Cefoxitin FOX 16 R 8 S
30 EURL S-11.5 1 Ceftazidime TAZ 2 S 8 R
30 EURL S-11.5 2 Ceftazidime TAZ 2 S 8 R
34 EURL S-11.1 2 Imipenem IMI 1 S 4 R
37 EURL S-11.4 1 Tigecycline TGC 2 R 1 S
37 EURL S-11.5 1 Tigecycline TGC 2 R 1 S
37 EURL S-11.8 1 Tigecycline TGC 2 R 1 S
39 EURL S-11.4 1 Colistin COL 2 S 8 R
40 EURL S-11.1 2 Cefoxitin FOX 16 R 8 S
40 EURL S-11.3 1 Ceftazidime TAZ 4 R 1 S
40 EURL S-11.3 2 Ceftazidime TAZ 4 R 1 S
40 EURL S-11.8 2 Ertapenem ETP 0.12 R 0.06 S
42 EURL S-11.1 2 Imipenem IMI 1 S 4 R
42 EURL S-11.2 1 Sulfamethoxazole SMX > 1024 R 64 S
42 EURL S-11.5 1 Tigecycline TGC 2 R 1 S
42 EURL S-11.6 1 Sulfamethoxazole SMX > 1024 R 32 S
45 EURL S-11.1 2 Cefoxitin FOX 16 R 8 S
45 EURL S-11.3 2 Cefoxitin FOX 4 R 4 S
45 EURL S-11.5 1 Tigecycline TGC 4 R 1 S
45 EURL S-11.7 1 Tigecycline TGC 2 R 1 S
Presumptive ESBL + pAmpC Presumptive ESBL
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Lab no. Strain Antimicrobial Obtained MIC value
Obtained 
interpretation
Expected 
MIC-value
Expected 
interpretation
36 EURL C-11.5 Ciprofloxacin CIP = 0.25 S 4 R
36 EURL C-11.5 Streptomycin STR 8 R =  0.5 S
36 EURL C-11.5 Tetracycline TET <= 0.5 S 64 R
39 EURL C-11.5 Nalidixic acid NAL 16 S 64 R
45 EURL C-11.5 Ciprofloxacin CIP 2 S 4 R
45 EURL C-11.6 Gentamicin GEN = 0.5 R 1 S
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1 EURL-S11.1 OXA -48 Whole genome sequenced - - -
1 EURL-S11.1 TEM -1B - - - -
1 EURL-S11.2 SHV -2 - - - -
1 EURL-S11.3 CTX M-9 - - - -
1 EURL-S11.3 TEM -1B - - - -
1 EURL-S11.4 TEM -1B - - - -
1 EURL-S11.5 CTX M-65 - - - -
1 EURL-S11.7 CTX M-8 - - - -
1 EURL-S11.8 CTX M-3 - - - -
1 EURL-S11.8 OXA -1 - - - -
2 EURL-S11.1 OXA -48
PCR (published)
Dallenne C. et al.: Development of a set of multiplex 
PCR assays for the detection of genes encoding 
important ß-lactamases in Enterobacteriaceae.
- -
2 EURL-S11.2 SHV -2 Whole genome sequenced - - -
2 EURL-S11.3 CTX M-9 Whole genome sequenced - - -
2 EURL-S11.3 TEM -1B Whole genome sequenced - - -
2 EURL-S11.5 CTX M-65 Whole genome sequenced - - -
2 EURL-S11.7 CTX M-8 Whole genome sequenced - - -
2 EURL-S11.8 CTX M-1
PCR (published)
Dallenne C. et al.: Development of a set of multiplex 
PCR assays for the detection of genes encoding 
important ß-lactamases in Enterobacteriaceae
- -
2 EURL-S11.8 OXA -1 Whole genome sequenced - - -
4 EURL-S11.1 ACC - X PCR (published) - - -
4 EURL-S11.1 CMY - X PCR (published) - - -
4 EURL-S11.1 CTX - X PCR (published) - - -
4 EURL-S11.1 IMP - X PCR (published) - - -
4 EURL-S11.1 KPC - X PCR (published) - - -
4 EURL-S11.1 NDM - X PCR (published) - - -
4 EURL-S11.1 OXA -48 X PCR (published) - - -
4 EURL-S11.1 OXA - X PCR (published) - - -
4 EURL-S11.1 SHV - X PCR (published) - - -
4 EURL-S11.1 TEM -1 PCR (published) - - -
4 EURL-S11.1 VIM - X PCR (published) - - -
4 EURL-S11.2 CTX - X PCR (published) - - -
4 EURL-S11.2 OXA - X PCR (published) - - -
4 EURL-S11.2 SHV -12 PCR (published) - - -
4 EURL-S11.2 TEM - X PCR (published) - - -
4 EURL-S11.3 CTX M-9 PCR (published) - - -
4 EURL-S11.3 OXA - X PCR (published) - - -
4 EURL-S11.3 SHV - X PCR (published) - - -
4 EURL-S11.3 TEM -1 PCR (published) - - -
4 EURL-S11.5 ACC - X PCR (published) - - -
4 EURL-S11.5 CMY - X PCR (published) - - -
4 EURL-S11.5 CTX M-14 PCR (published) - - -
4 EURL-S11.5 SHV - X PCR (published) - - -
4 EURL-S11.5 TEM - X PCR (published) - - -
4 EURL-S11.5 TEM - X PCR (published) - - -
4 EURL-S11.7 CTX M-8 PCR (published) - - -
4 EURL-S11.7 OXA - X PCR (published) - - -
4 EURL-S11.7 SHV - X PCR (published) - - -
4 EURL-S11.7 TEM - X PCR (published) - - -
4 EURL-S11.8 CTX M-3 PCR (published) - - -
4 EURL-S11.8 OXA - X PCR (published) - - -
4 EURL-S11.8 SHV - X PCR (published) - - -
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype Gene number
Not 
detected 
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Not 
detected 
4 EURL-S11.8 TEM - X PCR (published) - - -
9 EURL-S11.1 OXA -48 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.1 TEM -1 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.2 SHV -12 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.3 CTX M-9 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.3 TEM -1 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.5 CTX M-14 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.7 CTX M-8 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.8 CTX M-15 PCR (published) JAC 2010;65;490-495 - -
9 EURL-S11.8 OXA -1 PCR (published) JAC 2010;65;490-495 - -
17 EURL-S11.1 OXA -48 PCR (published) van der Zee et al., 2014 -  
17 EURL-S11.1 TEM -1 PCR (published) Olesen et al. (2004) MDR, 10: 334-340 - -
17 EURL-S11.2 SHV -2a PCR (published) MedVetNet WP9; Weill et al., (2004) J Clinical Microbiol 42(6):2432-2437; - -
17 EURL-S11.3 CTX M-9 PCR (published) Batchelor et al 2005 - -
17 EURL-S11.3 TEM -1 PCR (published) Olesen et al. (2004) MDR, 10: 334-340 - -
17 EURL-S11.5 CTX M-65 PCR (published) Batchelor et al 2005 - -
17 EURL-S11.7 CTX M-8 PCR (published) Hopkins et al. (2006) Int J Antimicrob Agents, 27: 572 - -
17 EURL-S11.8 CTX M-3 PCR (published) Carrattoli J Clin Microbiol. 2008,46:103-8 - -
21 EURL-S11.1 OXA -48 PCR (published) Poirel, 2011 - -
21 EURL-S11.2 SHV -2a PCR (published) Melano 2006 - -
21 EURL-S11.3 CTX M-9 PCR (published) Edelstein 2003; Simarro 2000. - -
21 EURL-S11.5 CTX M-65 PCR (published) Edelstein 2003; Simarro 2000. - -
21 EURL-S11.8 CTX M-3 PCR (published) Edelstein 2003; Carattoli 2004. - -
25 EURL-S11.1 OXA -48 PCR (in-house) - - -
25 EURL-S11.1 TEM -1B PCR (in-house) - - -
25 EURL-S11.2 SHV -2a PCR (in-house) - - -
25 EURL-S11.3 CTX M-9 PCR (in-house) - - -
25 EURL-S11.3 TEM -1B PCR (in-house) - - -
25 EURL-S11.5 CTX M-65 PCR (in-house) - - -
25 EURL-S11.7 CTX M-8 PCR (in-house) - - -
25 EURL-S11.8 CTX M-1 PCR (in-house) - - -
32 EURL-S11.1 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.1 ACT - X PCR (published) Voets et al 2011  - -
32 EURL-S11.1 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.1 CTX - X PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.1 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.1 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.1 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.1 KPC - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.1 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.1 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.1 OXA -48 PCR (published) Voets et al 2011  - -
32 EURL-S11.1 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.1 TEM -1B PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.1 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.1 VIM - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.2 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.2 ACT - X PCR (published) Voets  et al.  2011  - -
32 EURL-S11.2 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.2 CTX - X PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.2 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.2 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.2 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.2 KPC - X PCR (published) Dallanne et al 2010 - -
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32 EURL-S11.2 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.2 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.2 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64; Voets  et al.  2011  - -
32 EURL-S11.2 SHV -12 PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.2 TEM - X PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.2 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.2 VIM - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.3 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.3 ACT - X PCR (published) Voets  et al.  2011  - -
32 EURL-S11.3 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.3 CTX M-9 PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.3 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.3 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.3 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.3 KPC - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.3 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.3 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.3 OXA - X PCR (published) Voets et al 2011;  J. Antimic.Chemothe(2009) 64 - -
32 EURL-S11.3 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.3 TEM -1B PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.3 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.3 VIM - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.5 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.5 ACT - X PCR (published) Voets  et al.  2011  - -
32 EURL-S11.5 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.5 CTX - PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.5 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.5 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.5 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.5 KPC - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.5 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.5 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.5 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64;Voets  et al.  2011  ; - -
32 EURL-S11.5 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.5 TEM - X PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.5 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.5 VIM - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.7 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.7 ACT - X PCR (published) Voets  et al.  2011  - -
32 EURL-S11.7 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.7 CTX M-8 PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.7 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.7 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.7 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.7 KPC - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.7 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.7 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.7 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64;Voets  et al.  2011  - -
32 EURL-S11.7 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.7 TEM - X PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.7 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.7 VIM - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.8 ACC - X PCR (published)  (Hasman et al. 2005) - -
32 EURL-S11.8 ACT - X PCR (published) Voets  et al.  2011  - -
32 EURL-S11.8 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
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32 EURL-S11.8 CTX M-3 PCR (published) PediatrInfectDisJ28:814-818 - -
32 EURL-S11.8 DHA - X PCR (published)  (Gonzalez-Sanz et al.2009) - -
32 EURL-S11.8 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.8 IMP - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.8 KPC - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.8 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999-37 - -
32 EURL-S11.8 NDM - X PCR (published) L. Poirel et al 2011  - -
32 EURL-S11.8 OXA -1 PCR (published) Voets  et al.  2011   J. Antimic.Chemothe(2009) 64 - -
32 EURL-S11.8 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 - -
32 EURL-S11.8 TEM - X PCR (published) AntimicrAgentsChemotherap2009 - -
32 EURL-S11.8 VEB - X PCR (published) Dallanne et al 2010 - -
32 EURL-S11.8 VIM - X PCR (published) Dallanne et al 2010 - -
33 EURL-S11.1 ACC - X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC
33 EURL-S11.1 ACT - X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
TCGGTAAAGCCGATGTTGCGG CTTCCACTGCGGCTGCCAGTT
33 EURL-S11.1 CMY -2 X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
TGGCCAGAACTGACAGGCAAA TTTCTCCTGAACGTGGCTGGC
33 EURL-S11.1 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S11.1 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.1 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG AACCCACGATGTGGGTAGC
33 EURL-S11.1 CTX M-8 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S11.1 CTX M-9 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.1 DHA - X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC
33 EURL-S11.1 FOX - X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG
33 EURL-S11.1 IMP - X
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GGAATAGAGTGGCTTAAYTCTC GGTTTAAYAAAACAACCACC
33 EURL-S11.1 KPC - X
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
CGTCTAGTTCTGCTGTCTTG CTTGTCATCCTTGTTAGGCG
Appendix 9a, page 5 of 8
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype Gene number
Not 
detected 
33 EURL-S11.1 MOX - X
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
GCTGCTCAAGGAGCACAGGAR CACATTGACATAGGTGTGGTGC
33 EURL-S11.1 NDM - X
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC
33 EURL-S11.1 OXA -48
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG
33 EURL-S11.1 OXA -1 X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.1 SHV - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.1 TEM - PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S11.1 VIM - X
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG
33 EURL-S11.2 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S11.2 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.2 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG AACCCACGATGTGGGTAGC
33 EURL-S11.2 CTX M-8 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S11.2 CTX M-9 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.2 OXA -1 X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.2 SHV - PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.2 TEM - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S11.3 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S11.3 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.3 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG AACCCACGATGTGGGTAGC
33 EURL-S11.3 CTX M-8 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
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33 EURL-S11.3 CTX M-9
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.3 OXA -1 X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.3 SHV - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.3 TEM - PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S11.5 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
: AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S11.5 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.5 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG                     AACCCACGATGTGGGTAGC
33 EURL-S11.5 CTX M-8 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S11.5 CTX M-9
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.5 OXA -1 X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.5 SHV - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. : CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.5 TEM - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S11.7 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S11.7 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.7 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG                     AACCCACGATGTGGGTAGC
33 EURL-S11.7 CTX M-8
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S11.7 CTX M-9 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.7 OXA -1 X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.7 SHV - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.7 TEM - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA            ACGCTCACCGGCTCCAGATTTAT
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33 EURL-S11.8 CTX M-1 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC                    AGCTTATTCATCGCCACGTT
33 EURL-S11.8 CTX M-2 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S11.8 CTX M-26 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
GCACGATGACATTCGGG AACCCACGATGTGGGTAGC
33 EURL-S11.8 CTX M-8 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S11.8 CTX M-9 X
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S11.8 OXA -1 PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S11.8 SHV - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S11.8 TEM - X PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
36 EURL-S11.1 CTX - X PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S11.1 IMP - X
PCR (published)
M.J. Ellington . 2007. Multiplex PCR for rapid detection 
of genes encoding acquired metallo-ß-lactamases. J. 
Antimicrob. Chemother. (2007) 59 (2):  321-322.  
GGAATAGAGTGGCTTAAYTCTC CCAAACYACTASGTTATCT
36 EURL-S11.1 KPC - X PCR (published) V. Schechner et.al.2009. J Clin Microbiol. 2009 Oct;47(10):3261-5. doi: 10.1128/JCM.02368-08 ATGTCACTGTATCGCCGTCT TTTTCAGAGCCTTACTGCCC
36 EURL-S11.1 NDM - X PCR (published) S.Mushtaq et. al. J. Antimicrob. Chemother. (2011) 66 (9): 2002-2005. doi: 10.1093/jac/dkr226 GGGCAGTCGCTTCCAACGGT GTAGTGCTCAGTGTCGGCAT
36 EURL-S11.1 OXA -48
PCR (published) Laurent Poirel, et.al. 2004 ANTIMICROBIAL AAC, Jan. 2004, p. 15–22 DOI: 10.1128/AAC.48.1.15–22.2004 TTGGTGGCATCGATTATCGG GAGCACTTCTTTTGTGATGGC
36 EURL-S11.1 SHV - X PCR (published) Briñas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.1 TEM -1B PCR (published) Briñas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S11.1 VIM - X
PCR (published)
M.J. Ellington . 2007. Multiplex PCR for rapid detection 
of genes encoding acquired metallo-ß-lactamases. J. 
Antimicrob. Chemother. (2007) 59 (2):  321-322.  
GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG
36 EURL-S11.2 CTX - X PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S11.2 SHV -2a PCR (published) Briñas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.2 TEM - X PCR (published) Briñas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S11.3 CTX M-9 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S11.3 SHV - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S11.3 TEM -1B PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.5 CMY -2 X
PCR (published) Schmidt et al. PLoS One. 2015 Jun 26;10(6):e0131672. doi:10.1371/journal.pone.0131672. AGACGTTTAACGGCGTGTTG TAAGTGCAGCAGGCGGATAC
36 EURL-S11.5 CTX M-14 PCR (published) Hasman et al.J Antimicrob Chemother. 2005 Jul;56(1):115-21 ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
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36 EURL-S11.5 SHV - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.5 TEM - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S11.7 CTX M-8 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S11.7 SHV - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.7 TEM - X PCR (published) Brinas et al.Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S11.8 CTX M-3 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S11.8 SHV - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S11.8 TEM - X PCR (published) Brinas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
59 EURL-S11.1 OXA -48 Whole genome sequenced - - -
59 EURL-S11.2 SHV -2 Whole genome sequenced - - -
59 EURL-S11.3 CTX M-9 Whole genome sequenced - - -
59 EURL-S11.5 CTX M-65 Whole genome sequenced - - -
59 EURL-S11.7 CTX M-8 Whole genome sequenced - - -
59 EURL-S11.8 CTX M-3 Whole genome sequenced - - -
59 EURL-S11.8 OXA -1 Whole genome sequenced - - -
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold and white font, were detected but not expected 
Note: TEM-1 does not confer ESBL-production and is as such not included as an expected result. TEM-1 or TEM-1B was, however, present in S-11.1, S-11.3 and S-11.4
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Genotypic characterization (optional); comments by participants
17 EURL S‐11.1 TEM‐1 was additionally found. It is just added as additional information, not as ESBL‐gene.
17 EURL S‐11.3 TEM‐1 was additionally found. It is just added as additional information, not as ESBL‐gene.
17 EURL S‐11.5 Gene was found with a group‐specific PCR. Validation of the type was done via sequencing.
21 EURL S‐11.7 Isolate resistant to Cefotaxime, but no genes were found. 
32 EURL S‐11.1 SPM Gene tested for/not detected  (L. Poirel et al 2011)
32 EURL S‐11.2 SPM Gene tested for/not detected  (L. Poirel et al 2011)  
32 EURL S‐11.3 SPM Gene tested for/not detected  (L. Poirel et al 2011)  
32 EURL S‐11.5 SPM Gene tested for/not detected  (L. Poirel et al 2011)  
32 EURL S‐11.7 SPM Gene tested for/not detected  (L. Poirel et al 2011)  
32 EURL S‐11.8 SPM Gene tested for/not detected  (L. Poirel et al 2011)  
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